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Abstract 
The human oestrogen receptor (hER) mediates some effects of the steroid hormone 
oestrogen and functions as a ligand-dependent transcription factor in the nuclei of 
oestrogen-sensitive cells. The measurement of hER levels in breast cancer biopsies 
provides useful clinical information regarding therapy and prognosis. The current study 
describes a monoclonal antibody raised against hER aa 497-507 which recognises a novel 
nuclear antigen. 
Monoclonal antibodies were raised by immunising mice with a synthetic fragment of the 
hER (aa 497-507) conjugated to keyhole lymphocyte haemocyanin. Thirty antibody-
secreting hybridomas were identified. Hybridoma supernatants were characterised by 
enzyme-linked immunosorbent assay (ELISA), immunological staining using MCF-7 cells, 
binding studies, and SDS-PAGE Western blotting. 
One supernatant (15F6) displayed nuclear staining in fixed MCF-7 cells. Staining could be 
abolished by pre-incubation of the supernatant with the aa 497-507 peptide and peptide 
conjugates, but not with an unrelated hER peptide (aa 256-275). This antibody also 
stained the nuclei of hER negative breast cell lines MDA-MB-231 and MDA-MB-330, the 
breast cell line T47D, and liver cell line HepG2. Immunological staining of human tissue 
sections reveal the antigen to be present in the nuclei of keratocytes in skin and tubule and 
luminal endothelial cells of the kidney. The antibody identified a 120 kD band on Western 
blots with cytosols prepared from human breast cell lines and in solubilised cells. The 
antibody does not precipitate 16a-iodooestradiol-Iabelled ER from MCF-7 cells. 
Expression-linked screening of the MCF-7 cDNA library with antibody 15F6 identified nine 
positive clones. Antibody staining could be blocked by pre-incubating the antibody with 
hER aa 497-507-BSA conjugate, but not with an unrelated hER peptide conjugate. The 
(260 bp) clones were found to be identical. Submission of sequence to BLAST protein and 
nucleotide databases revealed a lack of homology to known proteins and genes. Sequence 
was matched to expressed sequence tags (ESTs) from brain, liver/spleen, uterus, ovary, 
colon, heart, and placenta. 
iii 
To further define the epitope of antibody 15F6, the sequence was translated and three 
peptides containing potential epitopes, comparable to the hER aa 497-507 region, were 
synthesised and tested by ELISA. The putative epitope was shown to be contained within 
one of these peptides. 
iv 
Introduction 
1.1 The Human Oestrogen Receptor (hER) 
The human oestrogen receptor (hER) is a member of the steroid receptor superfamily, a 
family of related nuclear proteins that includes the receptors for other classes of steroid 
hormones, thyroid hormone, peroxisome proliferator, vitamin D, retinoids, and the orphan 
receptors (Kuiper et al., 1996; Evans, 1988). Collectively, these function as ligand-
dependent transcription factors, playing a central role in mammalian development by 
regulating the expression of a variety of target genes (Beato, 1989). 
The hER mediates some of the effects of oestrogen, a hormone which plays a role in many 
developmental and physiological processes, including embryonic and fetal development, 
development of female secondary sex characteristics, female reproductive cycle, 
maintenance of pregnancy, and fertility. The physiological responses generated by this 
hormone are tissue-specific and include tissue differentiation, growth, protein synthesis, and 
secretion, Knockout mice lacking functional oestrogen receptor are infertile and show 
abnormal phenotypical changes associated with the gonads, mammary glands, reproductive 
tracts, and skeletal tissues (Korach, 1994). 
The molecular cloning of the hER (Greene et aI., 1986) has allowed fordetailed structural 
and functional analysis, including the assignment of the various functions of the receptor 
(ligand binding, dimerisation, nuclear translocation, DNA binding and transactivation) to 
regions of the protein based on amino acid sequence homology to other members of the 
steroid receptor superfamily (Lewis et al., 1995, Truss & Beato, 1993). The hER has been 
divided into six functional domains denoted A-F (Kumar et al., 1987)(Figure 1). 
The hER resides primarily in the nuclei of oestrogen-responsive cells, both in the presence 
and absence of its ligand (King & Greene, 1984). In the absence of hormone, the receptor 
is complexed with a 90 kDa heat-shock protein (HSP90) and other proteins. Hormone 
binding induces a conformational change in the receptor which leads to release from 
HSP90, dimerisation, and binding to oestrogen-responsive elements CEREs) in the DNA of 
oestrogen-sensitive genes (Lewis et aI" 1995). 
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Figure 1. Structural and functional domains of the human oestrogen receptor (hER). 
T AF; transcription activation function, NLS; nuclear localisation signal (Modified from 
Levenson & Jordan, 1994). 
1.2 Clinical Utility of the Human Oestrogen Receptor 
Epidemiological studies have revealed an association between lifetime exposure to 
oestrogen and incidence of breast cancer (Vessey, 1989; Henderson, 1988). There is a 
strong body of evidence pointing to oestrogen as being involved in the promotion of breast 
cancer and tumour growth (Lemieux & Fuqua, 1996). Endocrine therapy is designed to 
" 
counteract this process and consists of the administration of anti-oestrogens which bind the 
hER without causing transcriptional activation. 
Clinically, the most important application for the measurement of hER content is to 
-
identify patients with breast cancer who may benefit from endocrine therapy. In addition, 
hER status may provide prognostic information and add to our understanding of hER 
biology. With regards to prognosis, the presence of hER in tumours has been associated 
with prolonged disease-free and overall survival (Knight et al., 1977). 
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Generally, tumours which lack ER and progesterone receptor (PR) behave more 
aggressively than ERIPR positive tumours (Sluyser, 1992). The predictive value of ER 
status with regard to response to endocrine therapy and prognosis is not completely 
reliable; measurement of PR status further improves the ability to predict clinical outcome. 
For instance, approximately 75% of patients with advanced hERIPR positive tumours 
respond to the anti-oestrogen drug Tamoxifen, whereas 10% of patients with hERIPR 
negative tumours respond to the same extent (Lemieux & Fuqua, 1996; Osborne e(al., 
1980). The remaining hER positive tumours are thought to fail to respond to endocrine 
therapy due to the emergence of a sub-population of mutated and truncated oestrogen 
receptors which function constitutively, ie enhance transcriptional activity independent of 
the hormone. In this respect, constitutively active receptors resemble the oncogenes in 
their activity (Sluyser & Mester, 1985). 
1.3 Measurement of the Human Oestrogen Receptor 
The advent of hybridoma technology has led to the development of monoclonal antibodies. 
These are extremely powerful research tools due to their high specificity of binding, their 
homogeneity, and their ability to be produced in unlimited quantities. The basis of 
hybridoma technology consists of the fusion of antibody-secreting cells isolated from the 
immunised animal with myeloma cells to provide an immortal somatic cell hybrid that 
secretes antibodies (Kohler & Milstein, 1975)(Figure 2). Antibodies made by this process 
are now utilised in various immunochemical techniques for the detection, purification, 
quantification and investigation of the hER, and provide several advantages over the 
previously used ligand binding approach, in which a radio-labelled hormone serves as a 
marker for the receptor to which it binds. 
The limitations associated with ligand binding techniques include the nature of the 
interaction between ligand and receptor (the interaction is non-covalent, increasing the 
likelihood of ligand displacement during experimental manipulations), failure of the ligand 
to detect receptors already occupied by endogenous hormone, and failure of the ligand to 
bind to partially denatured, truncated or mutated receptors that have lost their hormone 
binding ability (Greene & Jensen, 1982). Furthermore, ligand binding methods such as the 
dextran-coated-charcoal (DDC) assay require large specimens, and results from the assay 
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are dependent on cell viability and cell types present (ratio of stromal to malignant cells)(Al 
Saatietal., 1993). 
These limitations are largely overcome by the use of antibody-mediated methods. An 
additional advantage conferred by using monoclonal antibodies is tfie-- ability to obtain 
information about receptor content of individual cancer cells from biopsy samples. This is 
desirable in light of the cellular heterogeneity in both hER content and structure associated 
with breast tumour evolution. 
Commercial monoclonal antibodies to the hER are available (Al Saati et al., 1993), 
however, these are costly. As part of an ongoing monoclonal antibody-generation program 
at the Steroid Laboratory, Clinical Biochemistry Unit, Canterbury Health Laboratories, 
Christchurch, New Zealand, an attempt was made to develop a monoclonal antibody to the 
hER suitable for routine immunochemical quantification of hER content in tumour biopsies. 
Such an antibody has the potential to enhance/replace the ligand-binding assay that is 
currently in use at the Laboratory. 
To date, both monoclonal and polyclonal antibodies to the hER have been generated using 
purified hER (ICing & Greene, 1984), hER peptide-carrier protein conjugates (Traish et al., 
1990, Poutanen et al., 1992), or recombinant hER as the immunising antigen (Al Saati et 
al., 1993). While all three strategies were attempted within the Steroid Laboratory, only 
the peptide-conjugate approach proved successful. 
1.4 The Production of Anti-peptide Antibodies 
The use of anti-peptide antibodies (raised against synthetic peptides) may be preferable 
over antibodies raised against purified antigens. Synthetic peptides can be used to raise 
antibodies directed against previously uncharacterised proteins, given that some of the 
sequence for the protein of interest is available. If more knowledge is available about the 
protein in question, particular regions of a protein can be targeted specifically for antibody 
production. Such site-specific antibodies have both clinical and research applications 
(Lerner, 1982). 
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'Figure 2. The generation of monoclonal antibodies. Mice are immunised intra-
peritonal1y with peptide-carrier protein conjugates at 4 week intervals. Ten days following 
a third injection, the spleen is aseptically excised and splenic lymphocytes fused with mouse 
myeloma cells to produce immortal hybridomas. Successful fusions (hybridomas) are 
selected for through use of a selective media, such as AAT (ad~nine, aminopterin, 
thymidine) which blocks nucleotide synthesis. Genetic information imparted by myeloma 
cells allows hybridomas to activate an alternate synthetic pathway, and hence multiply. 
Hybridomas of interest can be isolated and cloned by limiting dilution techniques and 
screened by ELISA, radioimmunoassay, immunofluorescence or immunocytochemistry 
(Modified from Alberts e/ al., 1989), 
Previous knowledge of protein structure can overcome the main limitation of anti-peptide 
antibodies; while they may bind the denatured protein extremely well, they often fail to 
recognise the protein in its native configuration. The coupling of the peptide to a carrier 
protein overcomes a second problem which can be encountered with anti-peptide 
antibodies, namely that the peptide itself may not elicit an immune response, due to the 
small size. 
The peptide sequence should be carefully selected in order to obtain an antibody which 
recognises the native protein. Hydrophilicity, "mobility" and position of the sequence 
within the native protein are all useful criteria. Hydrophilicity is required but not sufficient 
to predict whether a given sequence will be located on the surface ora protein (Hopp & 
Woods, 1981). The "mobility" of the amino acid residues reters to their relative 
temperature as determined by NMR and X-ray crystallography. It has been suggested that 
high temperature regions represent areas of increased flexibility which are more likely to be 
epitopes (Westhof et at., 1984). The position of the sequence is also informative; 
sequences present at either the amino- or carboxy-terminus are often exposed, making 
good targets (Harlow & Lane, 1988). Regions which are known to contain binding sites 
are also an obvious choice. 
The hER aa 497-507 region was chosen as a likely epitope due to its hydrophilic nature, 
proximity to a putative dimerization domain (Lewis et at., 1995) and unique sequence as 
determined by homology searches. The latter characteristic ideally leads to the 
development of an antibody which does not cross-react with other proteins. 
1.5 Antibody Characterisation 
For anti;..peptide antibodies, it is necessary to investigate each antibody's ability to 
recognise the native protein in addition to the immunizing peptide. The enzyme-linked 
immunosorbent assay (ELISA) enables the recognition between antibody and peptide to be 
examined and quantified. The indirect ELISA is designed to quantify the amount of 
antibody that is able to bind specifically to antigen immobilized on a solid phase (microtitre 
plate) through use of a labelled second antibody and substrate (Figure 3). Immunoassays 
such as the ELISA, are amongst the most sensitive analytical techniques available for the 
clinical detection of antigens and antibodies in body fluids (Kricka, 1994). 
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Figure 3. The indirect enzyme-linked immunosorbent assay (ELISA). The 
assay allows monoclonal antibodies of interest to be tested for their ability to 
recognise the antigen they were raised against (eg hER aa 497-507). In a 
variation of the assay (right-hand side), competitive dose-response curves can 
be generated by adding increasing amounts of soluble antigen with the 
monoclonal antibody. 
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To determine whether recognition of the native hER is occurring, the radioimmunoassay 
(RIA) is an obvious choice as this is the method currently utilized for the measurement of 
hER levels in breast cancer biopsy samples at the Steroid Laboratory. In addition to this, 
immunocytochemistry and Western blotting can be used to determine the cellular location 
and molecular weight of the antigen respectively. These method(>employ the same 
principle as the ELISA; interaction between the primary antibody and antigen, signal 
amplification by use of a labelled second antibody which binds the primary antibody, and 
visualisation or quantification of this interaction through use of a substrate. The 
radioimmunoassay differs in this respect in that the antigen or ligand is labelled, rather than 
the second antibody. 
By uSing these methods, an integrated profile can be derived for each antibody, and 
characteristics of the respective antigen can be compared to the known size, location and 
hormone-binding properties of the hER in order to confirm whether or not the antibody in 
consideration recognises the hER. If the antibody recognises the hER, the next stage 
involves the setting up of an assay suitable for the routine determination of receptor levels 
in breast biopsy samples. 
The MCF-7 human breast cancer cell line was utilised for immunocytochemisty and 
Western blotting, as this cell line has been extensively used as a research model of human 
breast cancer (Brooks et al., 1984) and was available within the Steroid Laboratory. 
Amongst the notable qualities of this cell line are oestrogen-responsiveness and ease of 
culture. The MCF -7 cell line has proved instrumelltal in providing insight into the 
mechanisms whereby hormones affect cell proliferation and protein synthesis 
(Katzenellenbogen et aI., 19~7). 
1.6 Aims of the Study 
The initial aim of the study, as envisaged by the Steroid Laboratory, was to obtain a 
monoclonal antibody suitable for the routine determination of hER levels in breast tumour 
biopsy samples, using hER aa 497-507 as the immunizing antigen. While no such antibody 
was found, during the early stage of the antibody characterisation process it became 
apparent that one of the antibodies (15F6) recognises an antigen other than the hER, 
providing an opportunity for further research. 
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Homology searches of hER aa 497-507 in both peptide (BLASTX) and nucleotide 
(BLASTN) databases revealed homology to oestrogen receptors from chicken, mouse and 
rat, wheat gamma-gliadin precursor and yeast negative growth regulatory protein NG GRI 
(Figure 4). This lack of homology to known human proteins was taken as an indication 
that this protein could be novel. 
Specifically, the experiments were designed to: 
" characterise a panel of monoclonal antibodies for their ability to recognise the hER . 
.. verify that antibody 15F6 does not recognise the hER by immunological techniques . 
.. examine the cellular location of the antigen recognised by antibody .J.5F6 in available 
human cell lines and tissues by immunological staining . 
.. derive the epitope sequence recognised by monoclonal antibody 15F6 by ELISA 
competition experiments . 
.. screen a human breast cancer eDNA library with antibody 15F6 to obtain sequence for 
the respective antigen. 
The data presented in this thesis support the hypothesis that antibody 15F6 recognises a 
novel nuclear antigen which is present in a wide variety of human tissues. 
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B 
Human ER (aa 497-507) 
Chicken ER (aa 491-501) 
Mouse ER (aa 501-511) 
Rat ER (aa 502-512) 
c 
ERcDNA 
In I 
Wheat gamma-gliadin precursor (aa 62-70) 
Yeast negative growth regulatory protein 
LQQQHQRLAQL 
LQQQHRRLAQL 
LQQQHRRLAQL 
LQQQH~RLAQL 
QQQHQb.LAQ 
LQQQHQQLDQ 
NGRI (RNA-binding protein RBPl) (aa 289-298) 
Figure 4. Location and interspecies sequence comparison of hER aa 497-507 synthetic 
peptide. The chosen peptide corresponds to a ll-aa sequence lying in region E of the hER. 
The peptide sequence (using single letter aa abbreviations) is compared to equivalent ER 
sequences of the chicken, mouse and rat. Two non-human proteins with homology to this 
peptide are also shown. Non-identical amino acids are underlined. Sequence was obtained 
from a BLASTP search. 
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Methods and Materials 
2.1 Reagents and Materials 
All reagents used were of analytic (AR) grade; supplier details are listed in Appendix A. 
The sources of materials used are indicated in the text, with full supplier details listed in 
Appendix A. 
2.2 Buffers and Media 
Composition details of buffer, media and other solutions can be found.,in Appendix B. 
2.3 Peptides 
The hER aa 497-507 sequence was synthesized by Multiple Peptide Systems, and was 
greater than 96% pure by reverse phase HPLe. The peptides used for epitope definition 
studies were obtained from Chiron Mimitopes Pty. Ltd, and were approximately 50% pure 
as determined by mass spectrometry (Figure 5). 
hER aa 497-507 
Peptide # 1 
Peptide # 2 
Peptide # 3 
L Q Q Q H Q R L A Q L - NHz 
GQQQSQHGGSHP - NHz 
V Q H H Q H Q A A Q A L H LAS P Q Q Q S A I Y H - NH2 
T Q S P Q NSF P A A Q Q T V F T I H P S H V Q P - NH2 
Figure 5. Peptide sequences used for antibody competition experiments and ELISA epitope 
definition studies. 
2.4 Conjuga tiol1 of Peptides 
Peptides were coupled to keyhole lymphocyte haemocyanin O-<LH), bovine serum albumin 
(BSA), or thyroglobulin (TG) with glutaraldehyde according to the method of Harlow and 
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Lane (1988). Glutaraldehyde is a bifunctional coupling reagent that links two compounds 
primarily through their amino groups, forming a relatively stable linkage. 
Briefly, solutions of peptide (5 mg/ml in PBS) and carrier protein (3.5 mg/ml in PBS) were 
prepared, and equal volumes (1 ml of each solution) were added to a 5 mrvial containing a 
stirring bar. To this solution, an equal volume (2 ml) of 0.2% glutaraldehyde (in PBS) was 
added drop-wise, and allowed to incubate for 1 h at room temperature with constant 
stirring. This was followed by the addition of 1 ml of 1 M glycine (in PBS) and a further 
incubation of 1 h. PBS was filter-sterilised prior to use. Following coupling, the 
conjugates were dialysed overnight at 4°C against 1 L PBS and stored in aliquots at -20cC 
until required for immunisation, screening of culture supernatants or other studies. 
Coupling of the hER aa 497-507 peptide to KLH (for immunisation) and BSA (for 
screening of supernatants usmg ELISA) was performed by Dr John Lewis, Steroid 
Laboratory. 
The coupling procedure described above was also utilised for making the peptide 
conjugates used in ELISA epitope definition studies. In this case, peptides were coupled to 
TG. 
2.5 Immunisation and Cell Fusion 
Male RBFiDN mice (obtained from the Christchurch School of Medicine Breeding Colony, 
Christchurch, New Zealand) were immunised intra-peritoneally with 50 ~g of aa 497-507-
KLH conjugate in Freund's complete adjuvant (Sigma) at four week intervals. Ten to 
twelve days following a third or fourth injection, the spleen was aseptically excised and the 
splenic lymphocytes fused with FOXNY mouse myeloma cells using 50% PEG at a ratio of 
5:1 as previously described (Lewis et al., 1989). When hybridoma growth could be 
detected, supernatants were tested for antibody-binding activity using ELISA. Hybridomas 
producing potentially interesting antibodies were cloned by. limiting dilution and 
characterised. Immunisation, cell fusion and cloning were performed by Dr John Lewis, 
Steroid Laboratory. 
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2.6 Enzyme-linked Immunosorbent Assay (ELISA) 
Supernatants were screened by ELISA using 96-well microtitre plates (Nunc.) coated with 
the hER aa 497-507-BSA conjugate. To coat each plate, lOll I of peptide-BSA conjugate 
was added to lOml of6 M aqueous guanidine hydrochloride and IOOIlI added to each well. 
Following overnight incubation at 4°C, the plates were washed (4x) witfi wash buffer, and 
"blocked" using phosphate buffered saline (PBS) assay buffer, 150llVweil. Following 
blocking, 1 h at 20°C, the solution was removed and replaced with fresh PBS assay buffer, 
50IlVwell, followed by 50111 of culture supernatant/well. Plates were incubated for 2 h at 
room temperature and then washed (4x). The second antibody, goat antimouse Ig 
peroxidase (Amersham), was added (1001ll!well), at a dilution of 1 :2000 in PBS assay 
buffer for a further incubation of 2 h at room temperature. Substrate solution (100 
Ill!well) was added after final washing of the plates. Colour developmenf was terminated by 
the addition of lOOIll!well of 1.25 M H2SOJwell, and absorbance read at 492 nm. 
Dose-response curves were generated on coated microtitre plates (as described above), 
with varying doses of soluble peptide conjugates (in PBS assay buffer) and supernatants 
from the appropriate clone (in PBS assay buffer), with subsequent processing as described. 
Supernatants giving good dose-response curves (DRCs) were diluted (1: 10, 1 :20, 1:40 and 
1 :80, in PBS assay buffer), and the experiment repeated in order to determine the most 
sensitive part of the curve. 
2.7 Cell Lines and Tissue Culture 
The MCF-7 cell line was obtained from Dr Ian Holdaway, Department of Endocrinology, 
Auckland Medical School, Auckland, New Zealand, and the oestrogen-receptor negative 
cell lines MDA-MB 231 and MDA-MB 330 from Dr Rob Sutherland, Garvan Institute, St 
Vincent's Hospital, Darlinghust, Australia. 
Cells were grown in 50 ml culture flasks or on 8-chamber tissue culture microscope slides 
O'l"unc.) in a humidified atmosphere containing 5% CO2 in air at 37°C, and maintained in 
adherent monolayer culture in phenol red-free RPM1640 (Gibco) supplemented with 10% 
fetal calf serum and 2 mM glutamine. The culture media was replaced with fresh media 
every 3 to 4 days and cells were grown until nearly confluent. Prior to harvesting the cells, 
media was removed and the cells were gently rinsed with PBS (3x). Cells were harvested 
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by vigorous flushing with a pasteur pipette and cold PBS. Cells were pelleted by 
centrifugation at 2000 RPM for 20 min, the PBS aspirated, and cell pellets stored at -20°C 
until use for SDS-PAGE Western blotting. 
Cytosols for SDS-PAGE Western blotting were prepared by resuspehding cell pellets in 
500111 Tris-EDTA buffer and homogenising the cell suspension manually in a lOml Teflon 
homogeniser on ice. The homogenised solution was decanted into microcentrifuge tubes, 
spun at 14,000 RPM for 10 min at 4Q C, and the supernatants transferred to fresh 
microcentrifuge tubes and stored at -20°e. 
2.8 Immunological Staining 
Hybridomas identified as positive by ELISA screenmg were further investigated by 
immunochemical and immunofluorescent staining. Breast cell lines were grown on 8-
chamber tissue culture microscope slides until almost confluent. Prior to fixation, the 
medium was aspirated and adherent cells were gently washed with PBS (3x). 
For immunofluorescence labelling, cells were fixed with 2% paraformaldehyde in PBS 
(300llllwell) for 30 min at 20°e. Following fixation, the cells were re-washed with PBS 
(3x) and incubated with fetal calf serum (FCS, 300lll/well) for a further 30 min to minimize 
non-specific binding ofthe antibody. Following aspiration ofFCS, hybridoma supernatants 
were added (200~I/well) and incubated overnight at 20°C. The cells w·ere gently washed 
with PBS (3x), and 300111 goat antimouse IgG/M: fluorescein was added (1: 100 in PBS 
containing 1% BSA, Tago) for a 3 h incubation at 20°C. After final washing with PBS 
(3x), the chamber lining and sealing gasket were removed and coverslips applied to allow 
for viewing under UV and white light using an oil immersion lens. All washing and 
antibody solutions added to the cells were passed through sterile 0.451lm Millipore filters 
(Millipore Corporation). 
Breast cells processed for immunoperoxidase staining were fixed with 100% ethanol (300 
Ill/well) for 10 min at 20oe, followed by methanol (containing 0.03% H202, 300 Ill/well) for 
30 min at 4°e. The cells were gently washed with PBS (3x), and incubated with NSS 
(normal sheep serum, 1:10 in PBS, 300 ~lIwell) for 20 min at 20o e. Following aspiration 
of serum and washing with PBS (3x), hybridoma supernatants were added (1:10 in PBS, 
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200 ~I/well) for a 3 h incubation at 20°C. Cells were washed with PBS (3x), and sheep 
antimouse biotin was added (300 ~1/well, 1 :200 in PBS containing 1 % NSS, Amersham). 
Following incubation for 30 min at 20°C, cells were washed with PBS (3x) and avidin-
biotinylated HRP complex was added (300 ~l/well, 1:200 in PBS containing 1% NSS, 
Amersham) for a 30 min incubation at 20°C. . After final washing with PBS (3x), 
diaminobenzidine (DAB) substrate solution was added. Colour development was 
terminated by immersing the slides in distilled H20 after the desired staining intensity was 
achieved (10-20 min). The chamber lining and sealing gasket were removed and coverslips 
were applied to allow for viewing under the light microscope. The location (nuclear, 
cytoplasmic, both or neither) and intensity of staining were noted for each antibody. 
Of interest were antibodies displaying predominantly nuclear staining'-(since the hER is 
localised exclusively in the nuclei ofMCF-7 cells). Such antibodies were used for further 
immunoperoxidase staining experiments on two human breast cancer cell lines which do 
not express the hER (MDA-MB-231 and MDA-MB-330). Staining was compared to that 
of hER positive MCF-7 cells, 
Antibody 15F6 was also used to stain two available adherent human cell lines; the human 
breast cell line T47D and the human liver cell line Hep G2, obtained from the Department 
of Cell Biology, University of Auckland, Auckland, New Zealand and the Wistar Institute, 
Philadelphia, USA, respectively, 
Immunohistological staining with antibody 15F6 was performed on mounted human skin 
and kidney sections kindly provided by the Haematoiogyllmmunology Research Group, 
Christchurch School of Medicine, Christchurch, New Zealand. Following fixation (10 min 
in ice cold acetone), sections were dried (30 min under moving air) and blocked using 10% 
human serum in PBS (5 min). The blocking solution was replaced with antibody 15F6 
(1 : lOin TBS) and subjected to a 30 min incubation period, after which slides were washed 
with TBS (3x). Biotinylated goat antimouse Ig (1 :200 in TBS) was subsequently applied 
for a further 30 min period, followed by washing with TBS (3x) and the addition of 
streptavidin-alkaline phosphatase (1 :200 in TBS, Dako). After a final washing step, slides 
were immersed in Fast Blue substrate solution. Colour development was monitored under 
a light microscope, and the reaction stopped by washing with PBS. 
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Skin sections were double-labelled with 15F6 and VM-2, the latter of which allows for 
definition of the keratinocyte layer through staining of basal keratinocytes. VM-2 staining 
was performed as descibed above, while 15F6 staining was performed with goat antimouse 
Ig peroxidase (1:200 in TBS, Dako) and ABC subtrate. Slides were photographed on 
Kodak Gold 100 ASA film using an Olympus BX-SO equipped with'a, PM-30 camera 
system. 
2.9 Binding Studies 
Oestrogen receptor positive cytosols labelled with 16a-iodo-oestradiol (>1500 Ci/mmol, 
Amersham) were used to investigate hybridoma supernatants deemeq positive by ELISA. 
Human breast tissue cytosols were the 36000 g supernatants after homogenisation of 
tumour tissue in Tris-EDTA buffer. Protein content of cytosols was approximated by a 
modified Bradford assay (Bearden, 1978). 
Briefly, cytosol was diluted to 1 mg/ml protein with Tris-EDTA buffer and an equal 
volume of 16a-iodo-oestrodial diluted in Tris-EDTA buffer (200,000 dpm/ml) was added 
for an overnight incubation at 4°C. Aliquots of labeled cytosol (200111) were then 
incubated with 100111 of supernatant (1:10 in Tris-EDTA buffer) for 3 h at 4°C followed by 
100j.l1 donkey antimouse/rat IgG cellulose (Sac-Cel, IDS) for 30 min at 4°C. One ml of 
Tris-EDTA buffer was then added and the tubes centrifuged, supernatant aspirated and the 
pellet counted. Binding studies using lSF6 antibody and 16a-iodo-oestradiol were also 
carried out at pH 6.5 and also in the presence of 0.4 M KCI. These conditions have been 
shown to minimise the formation of hER dimers (Thole et al., 1991), an occurrence which 
could potentially result in masking of the antibody binding site and hence prevent antigen-
antibody interaction. 
Similar experiments were also carried out with 16a-iodo-oestradiol labeled cytosols which 
were treated with dextran-coated charcoal (DCC) prior to the addition of hybridoma 
supernatants. This has the effect of removing any unbound oestradiol. Controls were 
always run consisting of oestrogen receptor positive and negative cytosols and separation 
with dextran-coated charcoal rather than hybridoma supernatant. 
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2.10 Westem Blot Analysis 
Proteins from solubilised whole cells or cytosolic extracts were separated by SDS-
polyacrylamide gel electrophoresis (SDS-PAGE) using 10% acrylamide gels (Laemmli, 
1970), and electrophoretically transferred (2 h at 70 V) to nitrocellulose (Schleicher & 
Schuell) using a Bio-Rad Mini Protean II system. Lanes containin~g -molecular weight 
markers were cut off and stored in the dark at 4°. The filters for immunostaining were 
blocked overnight in Tris-buffered saline (TBS) containing 5% skim milk powder. 
The nitrocellulose was cut into strips and incubated with the individual hybridoma 
supernatants (1: lOin TBS) for 3 h. Strips were washed with TBS (3 x 5 min), and 
incubated with sheep anti mouse IgG peroxidase (1: 10,000 in TBS, Amersham) for 1 h. All 
incubation and washing steps were at room temperature with gentle agitation. Following 
washing (3 x 5 min with TBS), the nitrocellulose strips were taken into a darkroom, 
immersed in enhanced chemiluminescence (ECL) substrate for approximately 5 seconds, 
blotted on 1M Whatman paper to remove excess substrate and exposed for 1 min on 
Kodak X-OMAT AR film (Eastman Kodak Co.). After this short exposure, the filters were 
re-exposed for a further 20 min and developed at the Radiology Services, Christchurch 
Public Hospital, Christchurch, New Zealand. Protein bands were sized by comparison to 
molecular weight markers (Kaleidoscope prestained standards, BioRad). 
2.11 Isotyping of Antibody 15F6 
The antibody was isotyped according to instructions provided with the Mouse Monoclonal 
Antibody Isotyping Kit (Amersham). The kit allows for accurate determination of class 
(IgA, IgG or IgM), the IgG subclass (Gl, G2a, G2b or G3) and light chain type (K or A) of 
the antibody through the use of nitrocellulose typing sticks which contain goat antibodies 
specific for the different types of peptide chain. 
Briefly, a typing stick was incubated with the hybridoma supernatant solution (1: lOin 
TBS) in a capped tube and incubated for 15 min at room temperature with agitation. After 
removal of the supernatant solution and washing (2 x 5 min with TBS), sheep antimouse 
peroxidase (1 :500 in TBS) was added and allowed to incubate at room temperature with 
agitation for 15 min. Following removal of the antimouse peroxidase solution, the typing 
stick was washed (2 x 5 min with TBS) and substrate was added for a further 15 min 
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incubation period. The substrate used was the ELISA substrate (refer Appendix) instead of 
the substrate included with the kit (4-chloro-1-napthol). After removal of the substrate, the 
typing stick was rinsed with distilled water (3 x) and the result (indicated by the appearance 
of purple coloured lines on the appropriate sections of the stick) interpreted immediately. 
2.12 Affinity Chromatography 
Antibody 15F6 was purified using an affinity column consisting of rat antimouse IgM 
coupled-Sepharose 4B (Pharmacia). Following overnight coupling, the antibody was 
eluted from the column with 2 M KI and dialysed overnight against PBS. The purified 
antibody was subsequently coupled to CNBr-activated Sepharose 4B (Fharmacia),(Lewis, 
1983). Prior to use, the coupled gel was washed with TED buffer. 
The gel was added to cytosols prepared from MCF-7 cells (in TED buffer) and incubated 
overnight at 4°C with gentle shaking. This mixture was transferred to a minicolumn and 
rinsed alternately with TED and TED containing 0.5 M NaCI to remove protein bound 
non-specifically to the column. Acetic acid (pH 2.5) was used to elute the "purified' 
protein fraction, which was dialysed overnight against distilled water. This solution was 
subsequently freeze-dried. 
2.13 ELISA and Western Blotting of the Purified Protein Extract .~ 
A simple ELISA of the protein extract purified by affinity chromatography was performed 
on a microtitre plate was coated with hER aa 497-507-BSA conjugate. The protein extract 
was diluted serially in PBS assay buffer (1:2,1:4,1:8,1:16 and 1:32) and 50]..L1 of each of 
the dilutions added/well, followed by the addition of 50]..LI of antibody 15F6 (diluted 1: 10). 
PBS assay buffer was substituted for protein extract in case of the control. The assay was 
processed as prescribed in section 2.6. 
A small amount of the extract was diluted in electrophoresis buffer and subjected to SDS-
PAGE. Following SDS-PAGE, half of the gel was stained for protein with Coomassie 
Blue while the remaining half was used for Western blotting. SDS-PAGE and Western 
blotting were performed in accordance with section.2.10. 
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2.14 Immunodiffusion and Immunoelectrophoresis of the Purified Protein Extract 
Immunodiffusion and immunoelectrophoresis were performed according to the methods of 
Turner and Hulme (1971). These techniques rely on the establishment of concentration 
gradients of antigen and antibody in a transport medium, such as an agarose gel, where 
immunoprecipitation can be observed at the antigen/antibody interface~ Both methods are 
excellent tools for investigating antigens. 
For immunodiffusion, 1% agarose gels were made by adding 500 mg of agarose in 50 ml of 
Tris-barbitone buffer and boiling this for 2 min in order to completely dissolve the agarose. 
After cooling to approximately 50°C, the gel was poured onto an 8 cm x 10 cm glass plate 
to a thickness of 2-3 mm. A period of at least 1 h was allowed for j)olymerisation of the 
gel, after which a pattern of small holes (3-4 mm in diameter) were punched in the gel; a 
central well surrounded by up to three peripheral wells, each separated from the central 
well by a distance of 3-4 mm. The protein extract (dissolved in Tris-barbitone buffer) was 
added to the central well, and antibody solutions of interest (anti-IgM, anti-human serum, 
anti-ceruloplasmin and antibody 15F6) to surrounding wells. Diffusion was allowed to 
proceed overnight under high humidity conditions, after which the gel was pressed 
overnight under several layers of filter paper, a stack of paper towels and a 500 g weight. 
The gel was subsequently fixed (10-15 min at 70°C), stained with Coomassie Blue (10 
min), rinsed with distilled water, destained (30 min with agitation), and dried (2-3 min at 
70°C). 
For immunoelectrophoresis, a 1% agarose gel was prepared (as described above), in which 
two small holes were made, approximately 2 mm accross, 10 mm apart and 3 cm from the 
edge of the gel (longitudinal orientation of gel). Human serum (containing bromophenol 
blue) was added to one of the wells and the protein extract to the other. The gel was 
placed in a gel tank and connected to the barbitone buffer reservoirs by paper wicks (3M 
paper, several layers). Electrophoresis, which distributes proteins in bands according to 
their respective mobilities, was performed for 2 h at 100 V. 
Following electrophoresis, a 2 mm wide longitudinal trough was cut at an equal distance 
between the two wells and filled with anti-human serum. Diffusion was allowed to proceed 
overnight under high humidity conditions, after which the gel was pressed, stained, 
destained and dried (as described above). Diffusion of the serum and antiserum results in 
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the formation of a series of characteristic precipitin arcs; the position of these arcs (ie 
mobility of respective proteins) can be compared to any arcs generated as a result of 
immunoreactivity between the protein extract and anti-human serum, hereby providing a 
means whereby contaminant human serum proteins can be detected. 
2.15 Bacterial Host Strains 
Bacterial strains used in this study were obtained from glycerol stocks kept at -80°C by Dr 
Martin Kennedy, Christchurch School of Medicine, Christchurch, New Zealand (Table 1). 
Bacteria were streaked onto agar plates and kept at 4°C for up to one month, at which 
point a single colony was taken and streaked onto a fresh plate. Single oolonies were taken 
from this stock plate for overnight liquid cultures as required. Strains were cultured under 
conditions described in the appropriate sub-sections. 
E.coli YI088 was used for DNA preparation and E.coli Y1090 for expression-linked 
library screening. This strain has a mutation in the 1011 protease to allow for increased 
fusion protein stability. E.coli DH5a was used for cloning. 
Strain 
DH5a 
YI088 
Y1090 
Table 1. 
Ref Genotype 
Woodcock, et al.(1989) F' endAl hsdR17 (r k - m k+) supE44 thi-l RecAl 
gyrA (Nair) relAl iJ(laclZYA-argF)U169 deaR 
( ¢80dlaciJ(lacZ)M1S) 
Huynh, et al. (1985) 
Huynh, et al. (1985) 
F- iJ{lac)U169 SupE SupF hsdR(rk- mk+) metE trpR 
JhuA2l proC::TnS (pMC9; Tetr AmP) NOTE: 
pMC9 is pBR322 with laclq inserted. 
F- iJ(lac)U16910n-100 araD139 lpsL(Strj supR 
l11crA tlpC22::TnlO (pMC9; Tetr AmP) 
Genotypes of Escherichia coli strains 
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2.16 Antibody Screening of the MCF-7 eDNA Expression Library 
Antibody probes serve a dual function; they allow for the cloning of genes as well as the 
isolation of their respective protein products (Young & Davies, 1983). The library 
employed in this study was constructed in the expression vector A.gtll. This vector permits 
insertion of foreign DNA into the p-galactosidase structural gene lacZ and promotes 
synthesis of hybrid proteins, which accumulate in E.coli strains defective in protein 
degradation (Ion mutants). These hybrid proteins, when embedded on nitrocellulose 
membranes, can be screened with antibodies with relative ease. 
Amongst the specific advantages of the A.gtll vector are its stability within the host cell 
and efficiency of response to induction (consisting of a rapid increase in copy number and 
high-level transcription of the foreign DNA. A.gt11 (lac5 nin5 c1857 S100) was derived 
from A.gt7 (lac5 b522 nin5) and A.gt4 (c1857 SlOO nin5) by Young and Davis (1983). 
The MCF-7 cDNA library was obtained from Professor Pierre Chambon, Institiut de 
Chimie Biologique, Faculte de Medecine, 11 Rue Humann, 67085 Strasbourg Cedex, 
France. 
The titre of the MCF-7 cDNA library, expressed as the number of plaque forming units 
(FPU) per ml, was determined by spotting IOIlI drops of serially-diluted phage (in SM 
buffer) onto a bacterial lawn on an LB + amp plate, and counting the number of plaques 
visible after an incubation period of6-8 h at 37°C. 
The library was plated out on five 17 cm x 22 cm LB plates (containing 1 rnM MgCh and 
50Ilg/ml Ampicillin). For each plate,S x 105 plaque forming units (PFU) were mixed with 
1 ml of log phase YI090 cells, pre-incubated for 20 minutes at 37°C and added to a 0.7% 
agarose· LB overlay (containing 10 mM MgS04 and 50Ilg/ml Ampicillin). Plates were 
incubated for 6-8 h at 37°C and overlaid with nitrocellulose. The nitrocellulose membranes 
were immersed in a 10 mM solution of isopropylthio-p-D-galactosidase (IPTG) in distilled 
water and allowed to air dry prior to use. IPTG functions to induce protein expression by 
inactivating the bacterial lac repressor. After a further 3 h incubation at 37°C, the 
nitrocellulose membranes were blocked overnight in TBS (containing 5% skim milk 
powder). 
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For antibody probing, the membranes were treated as follows. After three 5 minute washes 
in TBS (to remove residual skim milk powder), the membranes were incubated with the 
15F6 antibody (1: 10 in TBS) for 3 h with gentle shaking at room temperature. Following 
washing (3 x 5 min), the second antibody was applied (goat antimouse IgG alkaline 
phosphatase, diluted 1: 1000 in TBS, Tago) for a 1 h incubation. After a linal wash (3 x 5 
min), substrate (BCIPIl'mT) was added. Colour development was stopped after reaching 
the desired intensity «10min) by rinsing the membranes with distilled water. Membranes 
and library plates were stored at 4°C. 
Immunoreactive clones were plaque-purified by eluting appropriately located agar plugs in 
SM buffer overnight at 4°C, replating the eluates at approx. 100=200 FPU/plate, and 
repeating the above procedure until all plaques were 'positive'. 
To eliminate any false positives due to bacterial alkaline phosphatase production, the 
plaque-purified clones were re-screened with the more specific peroxidase substrate and 
second antibody sheep anti mouse IgG peroxidase (Amersham). Colour development was 
stopped after 20-30 min by rinsing the membranes with distilled water. 
The staining specificity of antibody 15F6 was confirmed by repeating the above procedure 
with the antibody pre-incubated with aa 497-507-BSA conjugate (l00~1 antibody and 
100~1 conjugate in 800~1 PBS, pre-incubated overnight at 4°C). A negative control 
consisted of the antibody pre-incubated with aa 256-275-BSA. 
2.17 Preparation of Agtll Lysates 
Liquid lysates from the immuno-positive clones isolated from the MCF-7 cDNA library 
were used for DNA preparation. These were produced by adding 1 00~1 log phase E.coli 
YI088 cells and approximately 108 PFU A bacteriophage to 10 ml LB containing 10 roM: 
MgS04, 0.4% maltose and 50~g/ml ampicillin. Cultures were grown at 37°C in a shaking 
incubator until the completion of lysis, usually after 6-8 h. Cultures showing no sign of 
lysis after 3 h were supplemented with extra phage. 100~1 of chloroform was added to each 
culture for the last 15 min of incubation in order to aid cell lysis. 
22 
2.18 Preparation of Agt11 DNA by Polymerase Chain Reaction (PCR) 
Lysates were subjected to PCR using custom primers, synthesized by Mr Howard Potter, 
Christchurch School of Medicine, Christchurch, New Zealand. The design of the forward 
primer (5' AATTAACCCTCACTAAAGGGGGTGGCGACGACTCCTGGAGCCCG 3') 
was based on a combination of the T3 universal primer sequence and··the Agt11 forward 
primer sequence. GC content and annealing temperature were calculated at 59% and 75°C 
respectively. The reverse primer (5' GTAATACGACTCACTATAGGGCTTGACACC 
AGACCAACTGGT AATG 3') incorporates the T7 universal primer sequence and the 
Agt 11 reverse primer sequence, with a GC content and annealing temperature of 45% and 
70°C respectively. 
Reactions were set up according to instructions provided with the Er:ONGase kit (Life 
Technologies) and run on a Hybaid Omnigene thermal cycler. Templates were denatured 
(94°C, 2min) and subjected to 30 cycles of denaturation (94°C, 30 sec), annealling (50°C, 
15 sec) and extension (nOC, 45 sec). PCR products used for sequencing were 
subsequently purified (High Pure PCR Product Purification Kit, Boehringer Mannheim) 
and visualised by gel electrophoresis using 1 % agarose gels and A pst markers obtained 
from the Cytogenetics and Molecular Oncology Unit, Christchurch School of Medicine, 
Christchurch, New Zealand. 
2.19 Restriction Digestion and Isolation orInsert DNA 
Inserts were digested with EcoR] (37°C, 65 min, Life Technologies) and visualised on 1% 
agarose gels. DNA fragments were isolated from agarose gels by centrifugation of gel 
slices through a sterile siliconised glass wool column. To construct such a column, the 
small end of a 1 ml pipette tip was cut off and glass wool lightly packed inside the opening. 
DNA fragments to be used as probes or for cloning were placed on top of the glass wool 
and the tip placed inside a 1.5 mt microcentrifuge tube. 
The microcentrifuge tube was then centrifuged at 14000 RPM for 15 min, and the fluid 
collected in the bottom of the tube was transferred to a fresh tube. The siliconised glass 
wool containing the compressed gel slice was discarded. The DNA was precipitated from 
the solution by adding 0.1 volumes of 3M sodium acetate (pH 5.2) and two volumes of ice 
cold ethanol and storing at -70DC for 20 min or until frozen. The precipitated DNA was 
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collected by centrifugation at 14000 RPM for 10 min, and washed twice with 70% ethanoL 
The DNA was then air-dried and resuspended in a small volume ofTE buffer (5-lOjll) and 
stored at -20°C until use. 
2.20 Sequencing 
Purified PCR products were quantified by comparison to molecular mass standards and 
sequenced by cycle-sequencing using a LI-COR Model 4000L sequencer, the SequiTherm 
Long-Read Cycle Sequencing Kit (Epicentre Technologies) or Thermo Sequenase 
Fluorescent Labeled Primer Cycle Sequencing Kit (Amersham) and T3 and T7 fluorescent 
primers (LI-COR). PCR-sequencing was carried out according to instructions supplied 
with each kit. 
Briefly, a mixture containing template DNA (50-250 fmol), labelled primer (ljll), lOx 
sequencing buffer (2.5 lll), thermostable DNA polymerase (1ll1) and deionised water (to 
bring volume up to 17 lll) was made up and 4 III added to each of four 0,5 ml 
microcentrifuge tubes containing the ddNTPs G, A, T, and C, on ice. After the addition of 
one drop of mineral oil to each tube and brief centrifugation to separate the oil from the 
reaction mixture, templates were denatured (92°C, 2 min) and subjected to 30 cycles of 
denaturation (92°C, 30 sec), annealling (SO°C, 15 sec) and extension (70°C, 15 sec). Stop 
solution (4lll) was added to each tube and 1.5 lliloaded onto the sequencing gel. Several 
sequencing reads in both directions were performed to eliminate sequencing errors and 
ambiguities. All sequencing was performed at the Cytogenetics and Molecular Oncology 
Unit, Christchurch School of Medicine, Christchurch, New Zealand. 
2.21 J2p Labelling, Plaque Lift and Library Screening 
One of the inserts (3B) was labelled with 32p_dNTP using the RTS RadPrime DNA 
Labelling System (Life Technologies). In order to examine sequence identity across clones, 
a plaque lift was done. lOll I of each lysate (I 07 FPU/ml) was spotted onto an LB plate 
with 0.5% agarose overlay containing IOOlll Y1090 cells, and incubated for 8 h at 37°C. A 
negative control (consisting of a 260 bp hER cDNA) was included. A nitrocellulose 
membrane was placed on the plate for 1 minute, after which the membrane was transferred 
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to denaturation solution for 30 seconds followed by neutralisation solution, and finally 
2XSSC, DNA was fixed in a UV Stratalinker. 
The membrane was prehybridised at 65°C for 2 h in modified Church Buffer (Church, 
1984), containing 500~1 of salmon sperm DNA. Subsequent addition of the probe was 
followed by an overnight incubation at 65 DC. Non-specific and unbound probe were 
removed during three 15-30 minute washes in 2 X SSC (Ix) and 0.1 X SSC containing 
0.1 % SDS (2x). The membrane was exposed on Kodak X-OMAT AR film for 5 h at -
80DC and developed at Radiology Services, Christchurch Hospital, Christchurch, New 
Zealand. 
For library screening, the MCF-7 cDNA library was plated out on four 17 cm x 22 cm 
plates at a density ofapprox. 5 x 105 FPU/plate. After 6-7 h, the plates were overlaid with 
Hybond-N+ membrane (Amersham) and processed as above. Exposure times varied from 
3-8 days depending on age of probe and number of previous uses. 
2.22 Bioinformatics 
Computational analysis of cDNA sequences was performed using BLAST (Basic Local 
Alignment Search Tool), accessed via e-mail «blast@ncbLnlm.nih.gov» at the National 
Center for Biotechnology Information (NCBI). BLAST represents a family of programs 
which utilise algorithms in order to detect similarity between the submitted or query 
sequence and sequences present in the nucleotide or protein databases (Altschul et aI., 
1990). 
BLASTN searches against a non redundant nucleotide database were used to check for 
matches to previously identified human genes. BLASTX searches against a non redundant 
protein database were used to translate the obtained cDNA sequence into the six possible 
reading frames and check these for homology to known proteins. Expressed Sequence Tag 
(EST) entries were retrieved from the EST database (dbEST). This database contains over 
343,000 expressed sequences (cDNA or mRNA) for which no information is available 
besides sequence (ie random cDNAs and end sequences). This corresponds to a significant 
proportion of all human genes and constitutes and invaluable tool for the molecular and 
functional characterisation of human genes. Sequences isolated from this database were 
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resubmitted in order to obtain overlapping ESTs (EST walking). Searches were repeated 
on a regular basis (every four to eight weeks). 
Translation of the 260 bp sequence into all six possible reading frames was done by using 
GCG software. 
2.23 Epitope Definition 
Based on sequence translation data (fig 27), it was speculated that the epitope, or antigenic 
determinant, recognised by antibody 15F6 was likely to be contained within open reading 
frame + I (ORF+ I). Similarity to hER aa 497-507 (amino acid identity and charge 
similarity) was used as the criteria for selecting regions to be synthesls~d as peptides and 
tested by ELISA (Figu re 6). 
Peptide 1. . .. . ' ................ Peptide 2 '" ........... """"<"'c,.'" .,., •.••. 
PA TPTGQQQSQHGG~HP AP SPVQlffiQ1!QAAQI\LHL~$~riQI:1S.m;W 
Peplide 3 
AGLAPTPPSMTPASNTQSPQN~FPt\:XQQTtYFT@sHYQPA 
Figure 6 The translated 260 bp sequence in open reading frame +1 (ORF+ 1). The areas highlighted 
were selected for peptide synthesis in order to define the epitope of antibody 15F6. 
Stock solutions of the peptides were prepared (IOOIlg/ml in PBS) and used to create a 
series of dilutions (l00, 50,25, 12.5,6.25 and 3.1251lg/ml, in PBS). 1001ll/weli of each 
dilution was added to a microtitre plate and incubated overnight at 4°C. Following 
blocking (l50llllwell of PBS assay buffer, 30 min), the plate was washed with wash buffer 
(4x) and antibody I 5F6 (1:20 in PBS) was added for a 2 h incubation at room temperature. 
The plate was washed (4x), and 1001ll/well of second antibody was added (goat anti mouse 
Ig peroxidase, 1: 1000 in PBS) for a 30 min incubation period. After a final washing (4x), 
substrate was added (I OOlll/well). Colour development was stopped by the addition of 
IOOlll/well 1.25 M I-hS04. The absorbance was read at 492 nm. 
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The above experiment was repeated with peptide 2; in this case a 1001lg/mi stock solution 
containing 0.1 % acetic acid was prepared in order to improve the solubility of the peptide. 
Dose-response curves using the peptides and peptide conjugates were also generated 
according to the methodology listed in section 2.6. 
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Results 
3.1 Dose-response Curves 
Thirty antibody-secreting hybridomas which recognised the hER a.a.497-507-BSA 
conjugate were identified by ELISA. Eight of these gave good dose-response curves 
(DRCs) over the range of peptide/peptide conjugates tested (O-lmg/ml). Further dilution 
of the hybridoma supernatants preserved the nRCs for four of these (lFl, lF2, l4Fll, 
lOB7). Dilution of the hybridoma supernatants did not always result in obtaining more 
sensitive DRCs; in some cases dose-sensitive response was reduced or lost. This was the 
case for supernatants lCl and 9FlO respectively (data not shown). HYbfidoma supernatant 
l5F6 did not generate a DRC, either undiluted or diluted, but is included for comparison 
(Figure 7). 
DRCs, using l5F6 and increasing doses of hER aa 497-507 peptide and peptide conjugates 
with BSA and KLH as controls are shown in Figure 8. The BSA-peptide conjugate exerts 
the strongest competitive binding influence over antibody l5F6, with the KLH-conjugate 
and unconjugated peptide having a lesser, but similar influence in terms of peptide 
concentration. BSA and KLH alone do not affect antibody binding to the coated plate. 
3.2 Binding Studies 
Binding studies revealed that none of antibodies were able to immunoprecipitate the native 
hER from l6a-iodo-oestradiollabelled cytosols above control levels (data not shown). 
3.3 Immunological Stnining 
Immunocytochemistry, using fixed MCF-7 cells and hybridoma supernatants identified one 
supernatant (15F6) showing predominantly nuclear staining (Figure 9). Other supernatants 
gave either no staining, cytoplasmic staining (Figure 10) or a mixture of cytoplasmic and 
nuclear staining, with varying intensities. Immunofluorescent staining tended to give less 
consistent staining patterns, however, nuclear staining with antibody l5F6 was observed. 
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Figure 7 Dose-response curves of a selection of monoclonal antibodies raised against hER aa 497-507. For each curve, 
antibody was added to microtitre plates coated with hER aa 497-507-BSA conjugate, along wi,th increasing doses of peptide 
(hER aa 497-507). 
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Figure 8 Dose-response curves generated by ELISA using antibody 15F6 (1:10 dilution). The antibody was added to 
hER aa 497-507-BSA coated microtitre plates, along with increasing doses of antigen (peptide or peptide conjugates). 
BSA and KLH were included to control for antigenicity generated by the conjugation of the peptide to the carrier protein. 
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The immunoperoxidase staining observed with antibody 15F6 could be completely 
abolished by pre-incubation of the antibody with the soluble peptide a.a.497-507 (10 
mg/ml), or a.a.497-507-BSA conjugate (1 mg/ml), and significantly reduced by pre-
incubation of the antibody with a.a.497-507-KLH conjugate (1mg/ml) or the soluble 
peptide (Img/ml). Staining was unaffected by pre-incubation of the antibody with either 
hER a.a.256-275-KLH (1 mg/ml) or a.a.256-275 (lor 10mg/ml) (Figure 11). 
Antibody 15F6 also stained the nuclei of two human breast cell lines which do not express 
the hER (MDA-MB-330 and MDA-MB-231), the human breast cell line T47D, and human 
liver cell line Hep2G. Staining of the hER negative cell lines could be abolished by pre-
incubation of the antibody with the soluble peptide and peptide conju~ates (Figures 12 and 
13). The staining of human tissue sections reveal the antigen to be present in the nuclei of 
keratocytes in skin (FiguresI4-16) and tubule and luminal endothelial cells of the kidney 
(FiguresI7-19). 
3.4 Western Blot Analysis 
Antibody 15F6 consistently identified a 120 kD protein in solubilized whole cells and 
cytosol extracts prepared from these cell lines (Figure 20). 
3.5 Isotyping of Antibody 15F6 
Isotyping revealed 15F6 to be an IgM K antibody. 
3.6 ELISA and Western Blotting of the Purified Protein Extract 
The protein extract obtained by affinity chromatography demonstrated immunoreactivity 
with antibody 15F6 by ELISA (Figure 21). Subjecting the extract to SDS-PAGE and 
staining the gel with Coomassie Blue allowed for the detection of several protein bands in 
addition to the (presumed) antigen (data not shown). Western blotting using antibody 
15F6 as a probe failed to generate a signal. 
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Figure 11. 
B 
o 
Immunoperoxidase staining of MCF-7 cell s using antibody 15F6. 
(a) Staining with 15F6. 
(b) 15F6 pre-incubated with hER a.a.497-507-BSA (1 mg/ml) . 
(c) 1SF6 pre-incubated with hER aa.4 97-S07-KLH (10 mg/mt). 
(d) lSF6 pre-incubated with hER a.a.497-S07 (lOmg/ml). 
(e) lSF6 pre-incubated with hER aa .256-27S (10mg/I11I) . 
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Figure 14. Photograph of human skin section showing location of basal keratinocytes 
(BK), hair follicles (F), dermis (D), epidermis (E) and associated keratin 
(K). All skin sections are double labelled with antibodies VM-2 (Fast Blue 
substrate) and 15F6 (AEC substrate) (x 100). 
Figure 15. Photograph showing nuclear staining of epidermal cells (E) surrounding hair 
follicle with antibody15F6 (AEC substrate) (x 400). 
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Figure 16. Photograph showing detailed nuclear staining of all layers of epithelial cells 
(EC) within the epidermal layer (E) using antibody 15F6 (Fast Blue sub-. 
strate). Basal keratinocytes (BK) are stained using antibody VM-2 (ABC 
substrate)(x 400). 
Figure 17. Photograph of human kidney section showing nuclear staining of tubule epi-
thelial cells (T) using antibody 15F6 (Fast Blue substrate) . Nuclear staining 
of glomeruli (G) is also visible in this section (x 100). 
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Figure 18. Photograph showing detail of nuclear staining of kidney tubule epithelial 
cells (T) using antibody lSF6 (Fast Blue substrate)(x 400). 
Figure 19. Photograph showing nuclear staining of luminal endothelial cells (E) in 
arteriole of kidney using antibody lSF6 (Fast Blue substrate)(x 400). 
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Figure 20. 
Figure 21 
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1 2 3 4 5 
SDS-PAGE Western blot of cytosol extracts from breast cancer cell lines. 
Lane 1; BioRad Kaleidoscope molecular weight markers. 
Lanes 2 and 4; MCF-7 cytosol stained with Coomassie Blue and 15F6 
respectively. 
Lanes 3 and 5; :MDA-MB-231 cytosol stained with Coomassie Blue and 
15F6 respectively. 
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ELISA competition experiment using monoclonal antibody 15F6 with 
varying dilutions of the protein extract on a hER aa 497-507-BSA coated 
assay plate. 
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3.7 Immunodiffusion and Immunoelectl"Ophoresis of the Purified Protein Extract 
Immunodiffusion between the protein extract and anti human serum gave a strong positive 
immunoprecipitation reaction, while no reaction was observed with either antibody 15F6 or 
anti ceruloplasmin (Figure 22). Immunoprecipitation did also occur between the protein 
extract and anti IgM (data not shown). 
Application of immunoelectrophoresis to the extract revealed the presence of human serum 
albumin as a contaminant (Figure 23). Unfortunately, the impurities present in the extract 
rendered it unsuitable for N-terminal sequence analysis. 
3.8 Antibody screening of the MCF-7 cDNA library 
Expression-linked screening of the MCF-7 cDNA library with antibody 15F6 resulted in the 
isolation of 22 immunoreactive clones. Re-screening of the plaque-purified clones with the 
more specific peroxidase substrate resulted in the elimination of 12 clones. Antibody 
specificity for the remaining ten clones was confirmed by an antibody-preincubation 
experiment, in which antibody staining was abolished by pre-incubating 15F6 with the 
a.a.497-507-BSA conjugate (Figure 24). 
Amplification by PCR, restriction enzyme digestion and agarose gel electrophoresis 
allowed for insert size determination; eight of these inserts were approx. 260 bp, one insert 
was approx. 100 bp, while the remaining insert did not give a PCR product. Sequence 
identity between at least eight of the inserts was confirmed by hybridisation with a 32p _ 
labelled insert as a probe. Five inserts were sequenced and found to be identical (data not 
shown). 
3.9 Bioinformatics 
Sequence was submitted to the BLASTN (nucleotide) and BLASTP (protein) databases for 
homology analysis. The results of the BLAST searches confirm the novelty of this 
sequence~ no gene or protein sequences were found to have sufficient homology (100% or 
slightly less depending on the presence of sequencing errors) to the complete submitted 
query sequence. 
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Figure 22. 
+ 
Figure 23 
1 
p 
3 
Immunodiffusion of the protein extract (P) against antibody 15F6 (1), anti 
human serum (2), and cellJioplasmin (3) The precipitin line between the 
extract and anti human serum indicates immllnoprecipitation 
p 
albumin 
arc 
• I 
Immunoelectrophoresis of the protein extract. Immunopreci pitation 
between anti human serum and serum results in the formation of a series of 
precipitin arcs, acting as a reference for the characterisation of contaminant 
protein(s). 
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Expression-linked sCI-eeni Ilg of the MCF-7 cDNA library (refer to Methods 
section for details of procedure). Immunoreactivity between expressed 
fusion protein from plaque-purified clones 4A2 and SB and antibody lSF6 
can be seen on the nitrocellulose strips. Speciticity of this interaction was 
demonstrated by pre-incubation of the antibody with hER aa 497-S07 BSA 
conjugate (ll11g/ml) prior to staining Pre-incubation of the antibody with 
an unrelated peptide (hER 2S6-275-BSA conjugate) was included as a 
negative control and did not abolish staining. 
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A low degree of homology to parts of several non-human genes and mRNA sequences was 
detected in the BLASTN database search. These include an alkaline protease gene from 
A.chrysogenum (48/75 positives, 64%), a rat pyruvate kinase gene (33/43 positives, 76%), 
a voltage-gated chloride channel mRNA from T.california (39/58 positives, 67%) and a 
cyclase associated protein mRNA from D.discoideum (37/54 positives,~ 68%). Homology 
to human DNA sequence between markers DXS6791 and DXS8038 on chromosome X 
was also found (35/49 positives, 71%)(Figure 25). The BLASTP search yielded results 
with a similar pattern; where homology to the query sequence was reported, it was only 
over very short stretches of amino acids and not complete. 
Submitting the sequence to the "est" database (dbEST) usmg the BLASTN program 
resulted in the isolation of several expressed sequence tags with partial of. complete overlap 
with the query sequence. These were resubmitted to the database in order to isolate 
additional overlapping clones. This process of EST walking allowed for the construction 
of a l.6 kb contig map (Fig 26). 
The largest of the ESTs is a l.2 kb fetal brain cDNA clone and contains a TATAA box. 
The origin of these ESTs (ie the tissue from which their respective cDNA library was 
constructed) has revealed the antigen to be present in brain, heart, liver, lung, spleen, colon, 
ovary, uterus and placenta (Table 2). 
Translation of the 260 bp sequence into the six possible reading frames (ORFs) yielded only 
one reading frame which did not contain stop co dons (Figure 27). This ORF contained 
several potential epitopes (ie regions with some homology to hER aa 497-507) and was 
therefore assumed to be the most likely reading frame. On the basis of this selection, three 
regions were chosen for peptide synthesis (section 2.3lFigure 6). 
3.10 Plaque Lift and Library Sueening 
At least eight of the clones isolated from the MCF-7 cDNA library hybridise to the 32p_ 
labelled probe under the conditions used for the plaque lift, leading to the assumption that 
they are likely to be identical. Re-screening of the MCF-7 library with the 32P-Iabelled 
probe was unsuccessful (data not shown). 
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Sequences producing High-scoring segment pairs: 
dbjlD009231APEALP 
gblM170D91RATPKRL2 
emb\X60433ITCVGCC 
emb z76735 HS24606 
gblu430271DDU43027 
A.chrysogenum gene for alkaline protea ... 
Rat pyruvate kinase gene, exons 3-9. 
T.californica mRNA for voltage-gated c .. . 
Human DNA sequence from PAC 24606, bet .. . 
Dictyostelium discoideum cyclase assoc .. . 
Score PIN) 
132 
125 
119 
119 
117 
0.40 
0.66 
0.998 
0.999 
0.99990 
>dbjID00923IAPEALP A.chrysogenum gene for alkaline protease, complete cds. 
Length 3152 
plus strand HSPs: 
Score = 132 (36.5 bits), Expect = 0.51, P = 0.40 
Identities = 40/75 (64%), positives = 48/75 (64%), strand = plus / plus 
14 CCCCCACTGGACAGCAGCAAAGCCAACATGGTGGAAGTCATCCTGCACCCAGTCCTGTTC 73 
II I 1111 II II II 11111111111 11 II I I I 11111 11 
Query: 
Sbjct: 904 CCTCAACTGCTCACCAACACCGCCAACATGGTCACCCTCCGCCGCCTCGCCGTCCTCCTC 963 
Query: 74 AGCACCATCAGCACC 88 
1111111 111 
Sbjct: 964 GGCGCCATCCCCGCC 978 
FigUl'e 25 Example of information retrieved from a BLAST search using the BLASTN 
program. BLASTN compares a nucleotide query sequence against a nucleotide sequence 
database in order to obtain sequence alignments. Five partial alignments to the query 
sequence (260 bp sequence isolated from the MCF-7 cDNA library) were reported. Shown 
below are details of one of the alignments; in this case the low degree of homology (64%) 
between nucleotide 14-88 of the query sequence and nucleotide 904-978 of theA. 
chrysogenun1 cDNA encoding alkaline protease. Homology of 100% or slightly less (to 
allow for sequencing errors) must be obtained in order to make the assumption that the 
query sequence is equivalent to a reported gene sequence. 
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510373 Colon 
595563 Ovary 
73509 Fetal spleen 
358904 Fetal heart 
ICRFp507G 16181 Brain 
MCF-7 cDNA Breast 
135227 Placenta 
207791 Fetalliverlspleen 
504843 Uterus 
Figure 26. Contig map generated by EST walking. The 260 bp cDNA isolated from the MCF-7library was submitted to dbEST in order to obtain 
sequence for available, overlapping clones. EST walking provides additional sequence data without the need to perfonn further library screening, thus 
saving considerable time and resources. In this case, EST walking also gives an indication of the tisstle types in which this antigen is expressed. 
A. 
1 CAGCTACCCC CACTGGACAG CAGCAAAGCC AACATGGTGG AAGTCATCCT 
51 GCACCCAGTC CTGTTCAGCA CCATCAGCAC CAGGCCGCCC AGGCTCTCCA 
101 TCTGGCCAGT CCACAGCAGC AGTCAGCCAT TTACCACGCG GGGCTTGCGC 
151 CAACTCCACC CTCCATGACA CCTGCCTCCA ACACGCAGTC GCCACAGAAT 
201 AGTTTCCCAG CAGCACAACA GACTGTCTTT ACGATCCATC CTTCTCACGT 
251 TCAGCCGGCG 
B. 
1 EREKDGS*RQ SVVLLGNYSV ATACWRQVSW RVELAQAPRG KWL-TAAVDWP 
51 DGEPGRPGAD GAEQDWVQDD FHHVGFAAVQ WG*LGI 
1 RLNVRRMDRK DSLLCCWETI LWRLRVGGRC HGGWSWRKPR VVNG*LLLWT 
51 GQMESLGGLV LMVLNRTGCR MTSTMLALLL SSGGS 
1 AG*T*EGWIV KTVCCAAGKL FCGDCVLEAG VMEGGVGASP AW*MADCCCG 
51 LARWRAWAAW C*WC*TGLGA G*LPPCWLCC CPVGV 
C. 
1 ATPPTGQQQS QHGGSHPAPS PVQHHQHQAA QALHLASPQQ QSAIYHAGLA 
51 PTPPSMTPAS NTQSPQNSFP AAQQTVFTIH PSHVQPA 
1 QLPPLDSSKA NMVEVILHPV LFSTISTRPP RLSIWPVHSS SQPFTTRGLR 
51 QLHPP*HLPP TRSRHRIVSQ QHNRLSLRSI LLTFS 
1 SYPHWTAAKP TWWKSSCTQS CSAPSAPGRP GSPSGQSTAA VSHLPRGACA 
51 NSTLHDTCLQ HAVATE*FPS STTDCLYDPS FSRSA 
Figure 27 Nucleotide and amino acid sequence of the 260 bp insert isolated by screening 
the MCF-7 cDNA library with antibody 15F6. 
A. nucleotide sequence of strand assigned as 'plus' strand 
B. possible amino acid translations of , minus' strand (strand complimentary to A) 
C. possible amino acid translations of 'plus'strand (A) 
Stop codons in B. and C. are denoted by * and correspond to TAA, TAG or TGA. 
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Unique Identifier Clone no. Source Length (bp 
embIZ78331IHSZ78331 ICRFp507G16181 fetal brain 1159 
gblAA1673121AA167312 595563 ovary 569 
gblH590451H59045 207791 fetal liver/spleen 557 
gblW947191W94719 358904 fetal heart 520 
gblAA1509561AA150956 504843 pregnant uterus 493 
gblT554691T55469 73509 fetal spleen 469 
gblAA0536671AA053667 510373 colon 443 
gblRJ 295 51RJ 2955 135227 placenta 363 
gblR124951R12495 128289 fetal liver/spleen 363 
gblRI 06041Rl 0604 128875 fetal liver/spleen 278 
Table 2 EST walking; details of expressed sequence tags isolated with the 260 bp sequence 
obtained in this study as the starting point. 
3.11 Epitope Definition 
For details of peptides selected for epitope definition experiments, refer to section 
2.3IFigure 6. 
Antibody 15F6 displays the greatest affinity for peptide 2 (Figure 28 A).:. The solubility of 
this peptide was extremely low (the peptide contains 11125 hydrophobic residues), making 
it difficult to use under standard assay conditions. Alternative solvents (dimethyl-
fonnamide, dimethylsulfoxide) did little to improve solubility; however, an increase in 
antibody binding can be seen when the peptide is dissolved in PBS containing 0.1% acetic 
acid (Fig 28 B). Dose-response curves, using peptide conjugates, show that the antibody 
has the greatest affinity for the peptide 2 conjugate (data not shown). It appears, therefore, 
that peptide 2 contains the epitope recognised by antibody 15F6. 
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Figure 28. Epitope definition studies using ELISA. 
A. Antibody 15F6 binding to peptides 1, 2 and 3 compared to binding of hER 
aa 497-507. 
B. Antibody 15F6 binding to peptide 2 under enhanced peptide solubilisation 
conditions. 
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Discussion 
4.1 Antibody 15F6 Recognises a 120 kD Nuclear Protein 
The data presented suggest that antibody 15F6 recognises a novel protein that is present in 
a variety of human tissues, including breast, liver, colon, spleen, kidney, heart, uterus, 
ovary, brain, skin and placenta. The presence of the antigen in every tissue tested so far is 
suggestive of a ubiquitous expression pattern. SDS-PAGE and Western blotting of human 
breast cell lines show this antigen to have a molecular weight ofapprox. 120 kD. 
Immunocytochemical staining offour breast cell lines and one liver cell line have shown this 
antigen to be localised predominantly in the nucleus of these cells. Immunological staining 
shows this antigen to be present in the nuclei of epithelial keratinocytes in skin and tubule 
epithelial cells of the kidney. Furthermore, the occurrence of nuclear staining of luminal 
endothelial cells in a nephritic arteriole suggests that the antigen is present in at least one 
cell population of the cardiovascular system. 
Immunocytochemistry, as performed in this study, has proved to be a valid tool for 
investigating the expression pattern of this antigen, with staining specificity demonstrated 
through antibody pre-incubation experiments. It would be of interest to test a wider range 
of human cell lines, however, the difficulty in obtaining and maintaining ,a range of human 
cell lines coupled to the requirement that these be preferentially adherent cell lines make 
immunocytochemical staining (avoiding cytocentrifugation) an unattractive option. The 
use of immunohistological staining would circumvent these difficulties, however, a source 
of human tissue for slide preparation is required. An alternative approach to characterising 
the antigen's expression pattern through immunological staining would be to perform 
mRNA hybridisation studies, commonly known as Northern blotting. 
4.2 Antibody 15F6 Does Not Recognise the Native hER 
Of interest is the degree of specificity shown by antibody 15F6. The antibody did not 
precipitate the hER from 16a-iodo-oestradiol labelled breast cytosols, even under 
conditions which favour dissociation of hER dimers (Thole et al., 1991). Western 
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blotting using this antibody failed to generate a signal in the region of the hER (67 JeD). 
These two findings indicate that the antibody does not recognise the native hER. 
4.3 Antibody 15F6 has a Degree of Specificity for the hER a.a.497-507 Region 
While the antibody does not recognise the native hER, there is a low and quantitatively 
unimportant degree of recognition of the hER aa 497-507 region. Using ELISA, dose-
response curves can be generated with the antibody and increasing doses of aa 497-507-
BSA conjugate, and to a lesser extent aa 497-507-KLH and the unconjugated aa 497-507 
peptide. 
This data is supported by the immunohistochemistry data where nuclear staining could be 
blocked by pre-incubating the antibody with either aa 497-507-BSA, aa 497-507-KLH or 
the unconjugated peptide. Staining could not be blocked by pre-incubation of the antibody 
with similar concentrations oran unrelated peptide, hER aa 256-275 and its conjugates, aa 
256-275-BSA and aa 256-275-KLH. It appears therefore that antibody 15F6 is specific for 
a region with some homology to hER aa 497-507. 
It is possible that the conjugation of the peptide to the carner protein (prior to 
immunization) induces a change in the biological epitope, resulting in a heterogenous 
population of conjugates with different orientations of peptide sequences. This would give 
rise to a diverse range of monoclonal antibodies. This is evident from the dose-response 
curves generated for each of the hybridoma supernatants. Of the 30 'positive' supernatants 
(ie displays reactivity with hER aa 497-507-BSA), only eight generated dose-response 
curves over the range ofO-lmglml soluble peptide, and seven of these had more sensitive 
dose-response curves than 15F6. However, none of these antibodies displayed nuclear 
staining with MCF-7 cells, or generated a signal on SDS-PAGE Western blotting using 
either MCF-7 cytosols or solubilized cells. Another possibility that could account for the 
diversity of the monoclonal antibodies produced is the presence of minor impurities in the 
immunising peptide. 
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4.4 Purification of the Protein 
An attempt to purify this antigen by affinity chromatography was partially successful; while 
the protein extract displayed immunoreactivity with antibody lSF6 by an ELISA 
competition experiment, no signal could be detected on a Western blot. SDS-PAGE was 
used to check the protein extract for purity, and revealed the presence of several additional 
proteins. Some of the immunoreactive contaminants could be identified through the use of 
immunodiffusion and immunoelectrophoresis. These were found to include human IgM 
(probably from the IgM affinity column used in the purification) and albumin, respectively. 
Albumin is probably the component that accounts for the strong reactivity seen between the 
protein extract and anti human serum with immunodiffusion. 
Immunoaffinity purification using monoclonal antibodies does not always work; cross-
reactivity is a problem observed with a subset of monoclonal antibodies (Harlow & Lane, 
1988). These antibodies bind to other antigens through shared epitopes. It is not possible 
to know whether this is occurring with the unidentified proteins in the extract. Proteins 
may also be co-purified with the antigen if the antigen is part of a complex under normal 
cellular conditions. 
An interesting observation made regards the dark green colour of the protein extract, 
suggesting either contamination or the presence of a copper-binding protein. 
Immunodiffusion of the extract against anti ceruloplasmin antibody shows that this protein 
is not a member of the ceruloplasmins (principal carriers of copper in numan plasma). A 
possible contaminant giving rise to this colour are the molybdate ions present in the TED 
buffer used during the purification procedure. 
Although immunoreactivity between the extract and antibody lSF6 was shown by ELISA, 
no precipin line was generated by immunodiffusion. This may be a property of the 
antibody, as some antibodies do not form precipitating complexes under the conditions 
employed. Alternatively, the lack of signal may be due to the greatly reduced sensitivity of 
immunodiffusion compared to the ELISA. 
Due to the failure to obtain enough antigen with sufficient purity, N-terminal sequencing 
was not performed. Increasing the number of cells used in the purification procedure 
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would increase the final yield of the antigen, however further purification procedures would 
have to be implemented in order to perform N-terminal sequencing. 
4.5 Sequence Analysis Does Not Reveal the Identity of the Antigen 
Submission of the DNA sequence obtained in this study to nucleotide (BLASTN) and 
protein (BLASTP) databases has not provided an identification for this antigen. The 
availability of ESTs provides some indication of the tissues which express the antigen as 
well as additional sequence. EST walking is a much cheaper, faster and less labour 
intensive means of obtaining sequence than repeat library screening. However, there are 
limitations on what can be done with the sequence; the relevant EST clones must be 
purchased and re-sequenced in order to provide accurate sequence ~efore assumptions 
about the translated geOne product can be made. 
Using EST walking in combination with sequencing, repeat library screening, or a 
combination of both, could be used to derive the complete cDNA structure, including the 
untranslated regions (UTs) at the 3' and 5' ends of the cDNA, a TATA box, initiation and 
termination codons, polyadenylation signals, and a poly(A) tail at the 3'end. A TATA box 
was identified in one/two of the ESTs. Downstream from this site are several possible 
initiation codons (consisting of methionine residues). 
With regard to the current study, ESTs have another potential use; tlrey. can be used as 
probes to define the chromosomal location of the respective gene. -The 1.2 kb EST 
referred to in this study could be used for chromosomal localisation using fluorescence in 
situ hybridisation (FISH). 111 situ hybridisation provides the most direct way to study the 
chromosomal localisation of DNA sequences (Lichter and Cremer, 1992). Other 
techniques which can be used for this purpose include somatic cell hybrid and radiation 
hybrid mapping, and identification of previously mapped yeast artificial chromosome 
(YAC) clones (Berry et al., 1995; Banfi et al., 1996). 
FISH allows for determination of location, size and number of specific DNA sequences in 
• 0 0 
mammalian cells, and involves hybridisation ofa selected DNA probe (minimum length of i 
kb) to the corresponding chromosomal region of metaphase chromosomes or interphase 
nuclei (Tkachuk et aI., 1991). Both the labelled probe DNA and the chromosomal DNA 
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are denatured and incubated together at a temperature below the melting point of the 
probe/chromosomal DNA duplex. The probe is labelled prior to use (for example, by 
incorporating a biotin label by nick translation) and the location of the bound probe is 
revealed by fluorescent staining (for instance, by incubation with fluorescein-avidin that 
binds specifically to biotin), using fluorescence microscopy. 
4.6 Use of Computational Sequence Analysis 
Computational analysis has become a much valued research tool in molecular biology; this 
is reflected by the number of software programs available to analyse structural and 
functional characteristics of a given DNA sequence. Sequences can be analysed for 
homology to known sequences (eg BLAST and FASTA programs), ~ssible intron-exon 
junctions and transcription-factor binding sites (eg PromotorScan, NetGene), or homology 
to known functional or structural motifs (eg BLOCKS, ProfileScan, MotifFinder). 
Common protein sequence motifs include nucleotide binding sites (ATP, GTP), phospho-
transferase sites, zinc fingers, nuclear localisation sites, and modification sites (eg N-
glycosylation, phosphorylation by protein kinases)(Hariow & Lane, 1988). 
Homology searching is amongst the most widely used means of identifying new genes. The 
most informative option consists of sequence translation (into all six possible reading 
frames) and using the result as a query against databases containing amino acid sequences 
(such as the BLASTX program) or functional motifs. If homologs wit~lmown functions 
can be found, the researcher gains information at very little cost and time compared with 
experimental analysis. However, not all newly discovered proteins have homologs in 
databases; it appears that the proportion is approximately half (Fickett, 1996). 
Information gained from computer homology analysis regarding potential functional motifs 
must be interpreted carefully; what level of homology to a given sequence is necessary 
before one can claim significant similarity? The criteria for finding potential functional 
motifs must carry sufl1cient stringency in order to avoid finding motif..s- which have no 
functional importance (Mikkelsen, 1993). 
Within the current study, computational analysis was restricted by the length of sequence 
obtained and lack of available homologs; while EST walking allowed for the construction 
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of a 1.6 kb contig map, effectively only the 260 bp sequence isolated in this study could be 
used due to the amount of errors induced by the single sequencing reads typical of 
sequences submitted to the EST database. Homology searching is particularly sensitive to 
changes in frameshift introduced by the omission of actual bases or addition of bases not 
present in the sequence. Such sequencing errors are extremely common and can only be 
circumvented by purchasing the ESTs and performing additional sequence reads. This 
option was investigated but not followed through due to the cost of the additional 
sequencing and time involved, but would be extremely worthwhile if this gene was to be 
sequenced in its entirety. 
Availability of the complete sequence would also allow for the use of intergrated gene-
finding programs (eg GRAIL, FGENEH, GeneParser). These give ~l overall predicted 
gene structure based on a set of intergrated algorithms, or rules, about gene 
structure/function relationships. Intergrated gene-finding programs have greater prediction 
accuracy than programs which recognise isolated features of genes. These programs are 
most efficient when tne input sequence encompasses exactly one entire gene and 
sequencing errors are absent. Furthermore, current algorithms cannot detect certain 
features of genes (eg alternative splicing and overlapping genes), and in some cases may 
not be particularly accurate (Fickett, 1996). 
Computational methods can be extremely efficient, however, they rely on knowledge 
gained from experimental methods. As experimental methods become::more powerful, it 
follows that the accuracy of computational analysis will increase also. In this sense, they 
are complementary and both will continue to play crucial roles in elucidating the structure 
and function of genes. 
4.7 Open Reading Frame +1 Does Not Contain Stop Codons 
Translation of the sequence obtained from the MCF-7 cDNA library into the six possible 
reading frames gave stop codons in all but one of the translations. Tl1is reading frame 
(ORF +1) contained several likely epit<?pes, ie regions with homology tohER aa 497-507 
that could be recognised by antibody 15F6. These regions were selected based on amino 
acid identity and charge similarity. 
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In order to confirm that ORF + 1 is the correct reading frame, it was envisaged that the 260 
bp insert could be cloned into the expression vector pFLAG, the recombinant protein 
purified and subjected to N-terminal sequencing. In this case, a recombinant protein 
containing the correct reading frame can be detected on a Western blot by antibody 15F6 in 
addition to the pFLAG antibody. The latter recognises a small marker peptide (1 kD) 
which becomes fbsed to the N-terminus of the recombinant protein. The marker peptide is 
encoded by the pFLAG vector, hereby providing a means of detecting the recombinant 
protein (International Biotechnology, Inc., Catalogue Number IB 13000). 
This strategy was attempted but proved unsuccessful (data not included). While the ligation 
was successful, the protein extracts made did not contain the appropriate size recombinant 
protein, as determined by SDS-PAGE and Western blotting. 
4.8 Peptide 2 Contains the Epitope Recognised by Antibody 15F6 
The antibody has the greatest affinity for peptide 2. This peptide is relatively long (25 
residues) and contains 11 hydrophobic residues, resulting in poor solubility. The addition 
of acetic acid improved antibody binding but still left fine needle-like crystals in solution, 
indicating poor solubility. To further define the epitope and improve peptide solubility, a 
series of shorter, overlapping peptides could be made and tested by ELISA. 
4.9 Potential Insight into Biological Function - Looking for Clues-
The following experimental approaches could be of some use in elucidating aspects of the 
function of this novel antigen; 
1. Examination of possible cell-cycle effects on the expression pattern of the antigen. This 
could be investigated by immunological staining of cells fixed during the different stages 
of the cell cycle. The observation that not all cell nuclei stain with similar intensities may 
provide some support for the notion that expression is cell-cycle linked.:.-
2. Characterisation of the effect of groyrth factors, hormones and other regulatory factors 
on the expression pattern of the antigen, within a cell type of interest. This could 
involve exposure to the factor during cell culture and comparison to cells grown under 
normal culture conditions. 
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In a situation such as that presented by this research, many options become available for 
experimentation, the challenge lying with the researcher. Monoclonal antibodies lend 
themselves to a wide variety of methodologies, hereby permitting a large degree of 
experimental freedom. 
At this time no further comment can be made about the biological significance of the 
antigen recognised by antibody 15F6. Gaining an understanding of its function is likely to 
involve a need to be able to detect and measure antigen levels, either for research or clinical 
purposes. Should this become the case, monoclonal antibody 15F6 will be an extremely 
valuable tool. 
55 
Reference List 
Al Saati, T., Clamens, S., Cohen-Knafo, E., Faye, lC., Prats, H, Coindre, lM., Wafflart, 
J., Caveriviere, P., Bayard, F., Delsol, G. (1993). Production of monoclonal 
antibodies to human estrogen-receptor protein (ER) using recombinant ER (RER). 
Int. J. Cancer 55:651-654. 
Altschul, S.F., Gish, W., Miller, W., Myers, E.W. & Lipman, D.l (1990). Basic local 
alignment search tool. J. Mol. BioI. 215:403-410. 
Banfi, S., Borsani, G., Rossi, E., Bernard, L., Guffanti, A, Rubboli~ F:, Marchitiello, A, 
Giglio, S., Coluccia, E., Zollo, M., Zuffardi, 0., Ballabio, A (1996). Identification 
and mapping of human cDNAs homologous to Drosophila mutant genes through 
EST database searching. Nature Gen. 13:167-174. 
Bearden, J.C. Jr. (1978). Quantitation of submicrogram quantities of protein by an 
improved protein-dye binding assay. Biochem. Biophys. Acta 553:525-529. 
Beato, M. Gene regulation by steroid hormones. Cell 58:335-344. 
Brooks, S.C., Hansen, E.R., Saunders, D.E., Battelli, M.G., Shafie, S.M. - (1984). Effect 
of growth on the estrogen receptor levels in MCF-7 cells. Cancer Res. 44:3724-
3729. 
Church & Gilbert. (1984). Genomic sequencing. Proc. Natl. Acad Sci. USA 81:1992-
1993. 
Evans, R.M. (1988). The steroid and thyroid hormone receptor superfamily. Science 
240:889-895. 
Fickett, lD. (1996). Finding genes by computer: the state of the art. Trends in Genetics 
12(8):316-320. 
56 
Greene, G.L., Gilna, P., Waterfield, M., Baker, A., Hort, Y., Shine, 1. (1986). Sequence 
and expression of human estrogen receptor complementary DNA. Science 
231:1150-1154. 
Greene, G.L., Jensen, E.Y. (1982). Monoclonal antibodies as probes for estrogen 
receptor detection and characterization. J. Steroid Biochem. 16:353-359. 
Harlow, E., Lane, D. (1988). Antibodies: a laboratory manual. Cold Spring Harbor 
Laboratory. 
Henderson, B.E., Ross R., Berstein, L. (1988). Estrogens as a cause of human cancer. 
Cancer Res. 48:246;.253. 
Hopp, T.P. & Woods, KR. (1981). Prediction of protein antigenic determinants from 
. amino acid sequences. Proc. Natl. Acad. Sci. 78:3824-3828. 
Katzenellenbogen, B.S., Kendra, KL., Norman, M.J., Bethois, Y. (1987). Proliferation, 
Hormonal Responsiveness, and Oestrogen Receptor Content of MCF-7 Human 
Breast Cancer Cells Grown in the Short-Term and Long-Term Absence of 
Estrogens. Cancer Res. 47:4355-4360. 
King, W.1. & Greene, G.L. (1984). Monoclonal antibodies localise oeltrogen receptor in 
the nuclei of target cells. Nature 307:745-747. 
Knight, W.A., Livingston, R.B., Gregory, E.J., McGuire, W.L. (1977). Estrogen receptor 
as an independent prognostic factor for early recurrence in breast cancer. Cancer 
Res. 37:4669-4671. 
Kohler, G. & Milstein, C. (1975). Continuous cultures of fused cells secreting antibody of 
predefined specificity. Nature 256:495-497. 
Korach, KS. (1994). Insights from the study of animals lacking functional estrogen 
receptor. Science 266:1524-1527. 
57 
Kricka, L.J. (1994). Selected strategies for improving sensitivity and reliability of 
immunoassays. Clill. Chem. 40(3):347-357. 
Kuiper, G.G.l.M., Enmark, E., Pelto-Huikko, M., Nilson, S., Gustafsson, 1. (1996). 
Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc. 
Natl. Acad Sci. USA 93:5925-5930. 
Kumar, V., Green, S., Stack, G., Berry, M., lin, J., Chambon, P. (1987). Functional 
domains of the human estrogen receptor. Cell 51 :941-951. 
Laemmli, u.K. (1970). Cleavage of structural proteins during the assembly of the head of 
the bacteriophage T4. Nature 227:680-685. 
Lemieux, P., Fuqua, S. (1996). The role of the estrogen receptor in tumor progression. J. 
Steroid Biochem. Molec. BioI. 56(1-6):87-91. 
Lerner, R.A (1982). Tapping the immunological repertoire to produce antibodies of 
predetermined specificity. Nature 299:592-596. 
Levenson, A.S., Jordan, V.c. (1994). Transfection of human estrogen receptor (ER) 
eDNA into ER-negative mammalian cell lines. J. Steroid Biochem. Molec. BioI. 
51(5/6):229-239. 
Lewis, F. V., Parker, M.G., King, R.J.E. (1995). Molecular modelling of the human 
estrogen receptor and ligand interactions based on site-directed mutagenesis and 
amino acid sequence homology. J. Steroid Biochem. Molec. BioI. 52(1):55-65. 
Lewis, J.G. (1983). 1X2HS Glycoprotein: functional studies. A thesis submitted for the 
degree of Doctor of Philosophy in Medicine at the University of Otago, New 
Zealand. 
Lewis, J.G., Robertson, J.M., Elder, P.A ·(1989). A monoclonal antibody to a 48 K 
antigen in oestrogen-dependent human breast cancer cells. J. Steroid Biochem. 
33:171-178. 
58 
Lichter, P., Cremer, T. (1992). Chromosome analysis by non-isotopic in situ 
hybridization. In: Human cytogenetics: a practical approach. Vol 1, 157-192. 
Rooney, D.E., Czepulkowski, B.H. (eds.). Oxford University Press, New York. 
Mikkelsen, T. (1993). Interpreting sequence motifs: a cautionary note. Trends in 
Genetics 9(5): 159. 
Osborne, C.K., Yochomowitz, M.G., Knight, W.A, McGuire, W.L. (1980). The value of 
estrogen and progesterone receptors in the treatment of breast cancer. Cancer 
46:2884-2888. 
Poutanen, M., Maentausta, 0., Isomaa, V., Joappila, P., Vihko, R. Inununohistochemical 
detection of human estrogen receptor with region D-specific antipeptide antibodies. 
J. Steroid Biochem. Molec. Bioi. 43 :311-317. 
Sluyser, M. (1992). Role of estrogen receptor variants in the development of hormone 
resistance in breast cancer. Clin. Biochem. 25:407-414. 
Sluyser, M., Mester, J. (1985). Oncogenes homologous to steroid receptors? Nature 
315:546. 
Thole, HH, Junblut, P.W., Jakob, F. (1991). The proton-driven -dissociation of 
oestradiol-receptor dimers as a preparative tool. J. Biochem. 276~709-714. 
Tkachuk, D.C., Pinkel, D., Kuo, W.L., Weier, HD., Gray, J.W. (1991). Clinical 
applications of fluorescence in situ hybridization. GATA 8(2):67-74. 
Traish, AM., Ettinger, R., Kim, N., Marshak-Rothstein, A, Woitz, H.H. (1990). 
Development and characterisation of monoclonal antibodies to a specific domain of 
human estrogen receptor. Steroids 55: 196-208. 
Truss, M., Beato, M. (1993). Steroid hormone receptors: interaction with 
deoxyribonucleic acid and transcription factors. Endocrine Rev. 14(4):459-479. 
59 
Turner, M.W., Hulme, B. (1971). The plasma proteins: an introduction. Pitman Medical 
& Scientific Publishing Company Ltd., London, U.K. 
Vessey, M.P. (1989). The involvement of oestrogen in the development and progression 
of breast disease: epidemiological evidence. Proc. R. Soc. Edinb. 95B:35. 
Westhof, E., Altschuh, D., Moras, D., Bloomer, AC., Mondragon, A, Klug, A, Van 
Regenmortel, M.H.V. (1984). Correlation between segmental mobility and the 
location of antigenic determinants in proteins. Nature 311:123-126. 
Young, R.A, Davis, R.W. (1983). Efficient isolation of genes by using antibody probes. 
Proc. Natl. Acad. Sci. USA 80:1194-1195. 
60 
Appendix A : Reagents and Materials 
I Source of Reagents I 
All reagents used were of analytical (AR) grade and obtained from the following suppliers; 
BDH Chemicals Ltd., Poole, England 
Sigma Chemical Co., St Louis, Missouri, USA 
Amersham, Buckinghamshire, England 
Gibco Life Technologies, 'Grand Island, New York, USA 
Boehringer Mannheim, D-6800 Mannheim 31, West Germany 
Pharmacia, Fine Chemicals AB, Uppsala, Sweden 
Bio-Rad Laboratories, Hercules, California, USA 
Source of Materials 
Amersham, Buckinghamshire, England 
Bio-Rad Laboratories, Hercules, California, USA 
Boehringer Mannheim, D-6800 Mannheim 31, West Germany 
Chiron Mimitopes Pty. Ltd., Clayton, Victoria 3168, Australia 
Dako, Carpinteria, CA 93013, USA 
Eastman Kodak Co., New York, USA 
Epicentre Technologies, Madison, WI 53713, USA 
Gibco Life Technologies, Grand Island, New York, USA 
IDS, Usworth Hall, Washington, NE37 3HS, England 
Irvine Scientific, Santa Ana, California, USA 
LI-COR, Inc., Lincoln, Nebraska 68504, USA 
Millipore Corporation, Bedford, MA -
Multiple Peptide Systems, San Diago, California, USA 
Nunc, Inc., 2000 North Aurora Road, Naperville, IL 60566 
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Pharmacia, Fine Chemicals AB, Uppsala, Sweden 
ScWeicher & SchueH, West Germany 
Sigma Chemical Co., St Louis, Missouri, USA 
Tago, Inc., Burlingame, CA, USA 
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Appendix B : Buffers and Media 
A.2.6 Enzyme-linked Immunosorbent Assay (ELISA) 
Phosphate Buffered Saline (PBS) Assay Buffer 
10 PBS tablets 
1 ml Tween 20 
1 g gelatin (dissolved in 100 ml distilled water by heating in microwave) 
Made up to 1 I with distilled water 
Wash Buffer 
23.4 g NaH2P04.2H20 
26.4 gNaCI 
3 ml Tween 20 
Made up to 3 I with distilled water, pH adjusfed to 7.4 with 5 M NaOH 
Substrate Buffer 
7.1 g Na2HP04 
5.25 g citric acid 
Made up to 1 I with distilled water 
Substrate 
50 ml substrate buffer 
20 mg OPD (o-phenylenediamine dihydrochloride) 
30 ~l hydrogen peroxide 30% w/v 
Prepared before use and stored in dark 
I A.2.S Immunological Staining 
Phosphate Buffered Saline (PBS) 
1 PBS tablet for every 100 ml of distilled water 
0.1 M Tris-HCI Buffer 
12.1 g Tris 
300 III H202 (30% w/v) 
Made up to 11, pH adjusted to 7.6 with cone HCl 
Diaminobenzidine (DAB) Substrate 
50 mgDAB 
100 ml 0.1 M Tris-HCl buffer 
Fast Blue substrate 
2 mg sodium AS phosphate dissolved in 100 III dimethyl formamide (DMF) 
10 mg fast blue salt 
6 III 1 M levamisole 
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10 ml 0.1 M Tris, pH 8.2 
AEC substrate 
10 mg AEC dissolved in 100 ~I ofDMF 
10 ml 0.05 M acetate, pH 5.1 
I A.2.9 Binding Studies I 
Tris-EDTA Buffer 
1.21 g Tris 
0.558 gEDTA 
4.84 g Na2Mo04 
154 mg dithiothreitol 
100 ml glycerol 
Made up to 1 I with distilled water, pH adjusted to 7.4 with cone HCI. 
I A.2.10 Western Blot Analysis 
Sample buffer 
4.0 ml distilled water 
1.0 ml 0.5 M Tris-HCI, pH 6.8 
80 ~I glycerol 
1.6 ml 10% (w/v) SDS 
0.4 ml 2-b-mercaptoethanol 
0.5 ml 0.05% (w/v) bromophenol blue 
Added in equal volumes to sample and heated at 95°C for 4 min before loading 
Electrophoresis buffer (5X) 
15 g Tris 
72 g glycine 
5 g SDS 
Made up to 1 I with distilled water, pH adjusted to 8.3 and diluted to Ix before use 
Transfer buffer 
6 g Tris 
28.8 g glycine 
L8 L distilled water 
200 ml methanol 
Tris-buffered saline (TBS) 
6.5 g Tris 
9 gNaCI 
1 ml Tween 20 
Made up to 1 I with distilled water, pH adjusted to 7.4 with cone HCI 
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Enhanced chemiluminesce substrate (ECL) 
This substrate was prepared by adding equal volumes of solutions 1 and 2: 
Solution 1 
100 ml 0.1 M Iris, pH 8.6 
400 III luminol stock (44 mg 5-amino-2,3 dihydro-l,4-phthalazinedione in 400 III 
dimethylsulfoxide (DMSO)) 
24 III acid stock (0.09 g 4-hydroxycinnamic acid in 1 ml DMSO) 
Solution 2 
100 ml 0.1 M Iris, pH 8.6 
80 III 30% w/v H 202 
I A.2.12 Affinity Chromatography 
TED buffer 
2.42 g Tris 
372 mgEDIA 
154 mg dithiothreitol ImM 
Made up to 1 I with distilled water, pH adjusted to 7.4 with conc HCl. 
A.2.14 Immunodiffusion and Immunoelectrophoresis 
Tris-barbitone buffer 
3 g barbituric acid 
4.6 g Iris 
8.9 g Na barbitone 
0.4 g Ca lactate 
Made up to 1 I with distilled water, pH adjusted to 8.8 with conc HC!. 
Coomassie Blue 
10 g Coomassie Brilliant Blue 
450 ml 70% ethanol 
100 ml glacial'acetic acid 
450 ml distilled water 
Destain 
95 ml distilled water 
95 ml 70% ethanol 
10 ml glacial acetic acid 
l A.2.IS Media I 
Luria Broth (LB) 
20 g Bacto Iryptone 
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109 yeast extract 
20 gNaCI 
Made up to 21 with distilled water, pH adjusted to 7.0 with 5 M NaOH, and autoclaved. 
Ampicillin stock solution 
15 mg/ml amp stocks were made up in distilled water. Stocks were filter-sterilised and 
stored at -20°C for a maximum of 3 weeks. 
LB + Amp plates 
300 mlLB 
4.5 g agar 
This was heated in a microwave until all agar had dissolved (approx. (; min) and allowed to 
cool. When cooled to 50°C, 1 mt amp stock was added and plates made by pouring 25 ml 
of media per petrie dish. Plates were left to set, inverted, and stored at 4°C for up to 2-3 
weeks. Prior to use, plates were dried inverted, without lids, for 1 h at 37°C. 
A.2.16 Antibody Screening of the MCF-7 cDNA Library 
SM buffer 
5.8 g NaCI 
2 g MgS04.7H20 or 0.98 g anhydrous MgS04 
6.5 g Tris 
0.2 g gelatin 
Made up to 11 with distilled water, pH adjusted to 7.5 with cone HCI, and autoclaved. 
Alkaline phosphatase (AP) buffer 
12.1 g Tris 
5.9 gNaCI 
1.2 g MgCh.6H20 
Made up to II, pH adjusted to 9.5 with cone HCI 
Alkaline phosphatase substrate 
Stock solutions 
1. SO mg/ml BCIP in 100% dimethylformamide (DMF) 
2. SO mg/ml NBT in 70% dimethylformamide 
100 ml AP buffer 
660 ~I NBT stock 
330 ~I BCIP stock 
Substrate was freshly prepared before use. 
Peroxidase substrate 
80 mg 4-chloro-I-napthol dissolved in 20 ml methanol 
120 III H202 
80ml TBS 
Substrate was freshly prepared before use. 
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A.2.19 Restriction Digestion of Agtll Bacteriophage DNA 
THE electrophoresis buffer (10 X stoch:) 
108 g Tris 
55 g boric acid 
3.7 gEDTA 
Made up to 1 I with distilled water. 
Agarose gels 
1 % agarose gels were made by adding 500 mg agarose to 50 ml TBE (1 X) buffer in a 
conical flask. The agarose was heated until completely dissolved (2 min in a microwave), 
and the gel cooled to approximately 50°C before pouring. Gels were allowed to set for 45 
min to 1 h before use. 
Loading dye (6 X) 
25 mg bromophenol blue 
25 mg xylene cyanol FF 
6 ml distilled water 
4 ml sucrose 
Ethidium bromide 
Made up as a 10 mglml stock solution, Sill of stock solution was added to the TBE 
electrophoresis buffer prior to use. 
TE (100 X stock) 
12.1 g Tris 
3,7gEDTA 
Made up to 100 ml with distilled water, pH adjusted to 8.0 with conc HCI, and autoclaved. 
Restriction digests 
DNA digests were performed in micro centrifuge tubes in either a 1O1l1 or 20111 volume, 
containing lOx buffer (one-tenth of final volume), RNAse (1 III of lOmglml stock), 
restriction enzyme (1-2Ill at IOU/Ill), DNA, and distilled water (to 1O1l1 or 20lll), Digests 
were performed at 37°C for 65m min in a heated water bath, after which the reaction was 
stopped at 7 SoC for 10-15 min in a heated block. 
A.l.U Plaque Lift and Library Screening 
Denaturation solution 
43.8 gNaCl 
10 gNaOH 
Made up to SOD ml with distilled water 
Neutralisation solution 
43.8 gNaCl 
60.S5 g Tris 
Made up to 500 ml with distilled water, pH adjusted to 8.0 with cone HCI. 
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Modified Church buffer 
Equal volumes of; 
10 % SDS 
0.5 M NazHP04 
Preheated to 65 Q C. 
20 x SSC (Standard Saline Citrate) 
175.32 g NaCI 
88.23 g sodium citrate 
Made up to 1 I with distilled water, pH adjusted to 7.0 with NaOH. 
Diluted as necessary with distilled water (ie 2 x SSC, 0.1 SSC). 
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Postscript 
On the 10th of March 1997, a final BLAST sequence search was made. 100% homology 
was reported between the sequence obtained in this study and part of the human mRNA for 
ataxin 2, also known as spinocerebellar ataxia type 2 protein (SCA2). Agreement was also 
found between the deduced reading frame, molecular weight, location and expression 
pattern given here and published information. The function of this protein remains 
unknown, however, its abnormal expression has been implicated in the neurodegenerative 
disorder spinocerebellar ataxia type 2, one of the dominant spino-cerebellar ataxias 
(SCAS)I-3. 
SCAs are part of a class of dominantly inherited neurodegenerative disorders, including 
Huntington's disease (HO) (ref in Sanpei), spinobulbar muscular atrophy (SBMA), and 
dentatorubral-pal1idoluysian atrophy (DRPLA). The mutation responsible for these disease 
phenotypes is expansion of an unstable trinucleotide repeat (CAG), encoding a 
polyglutamine stretch in the corresponding protein. The affected proteins are dissimilar 
except for the polyglutamine stretches, and are thought to have different functions. 
One of the strategies used to clone the SCA2 gene was expression-linked cloning, using a 
monoclonal antibody raised against the polyglutamine containing transcription factor TBP 
(TATA binding protein)l. This antibody has been shown to detect the pathological 
proteins present in HO, SCA1 and SCA3 patients using western blotting4 . Western blots 
give an apparent size of 150 kD for the mutant SCA2 protein, however, it has been 
suggested that a size of about 120-130 kD IS more realistic, given that expanded 
polyglutamine stretches are known to affect electrophoretic migration l . This is in 
agreement with the molecular mass predicted by examining eDNA structure; a mass of 124 
kD or 140 kD has been suggested depending on which one of two start (ATG) codons is 
utilized. The ATG codon predicted to give rise to the 124 kD product is in better 
agreement with Kozak's consensus sequence2. 
Western blot analysis of fractionated Iymphoblastoid cell lines reveals the presence of the 
SCA2 protein in the cytosolic fraction4. A similar result using western blotting was 
obtained in the current study, however, immunological staining shows a predominantly 
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nuclear localisation. It is likely that the protein is loosely associated with the nucleus under 
normal cellular conditions, partitioning into the cytosolic fraction under fractionating 
conditions for detection with western blotting. 
The expression pattern reported here is in agreement with Northern blot analysis. A 4.5 kb 
transcript was detected in brain, heart, placenta, liver, skeletal muscle and pancreas. The 
transcript was absent from lung and kidney2.3. No further tissues were tested. 
In conclusion, the evidence suggests that monoclonal antibody 15F6 specificalty recognises 
the SCA2 protein. This makes it an invaluable research tool with applications which could 
provide insight into the biology of SeA2. 
lImbert, G., Saudou, F., Yvert, G., Devys, D., Trottier, Y., Garnier, J-M., Weber, C., Mandel, J-L., 
Cancel, G., Abbas, N., Durr, A., Didierjean, 0., Slevanin, G., Agid, Y., Brice, A (1996). Cloning of the 
gene for spinocerebellar ataxia 2 reveals a locus with high sensitivity to expanded CAG/glutamine repeats. 
Nature Genetics 14:285-291. 
2 Sanpei, K, Takano, H., Igarashi, S., Sato, T., Oyake, M., Sasaki, H., Wakisaka, A., Tashiro, K, Ishida, 
Y., Ikeuchi, T., Koide, R, Saito, M., Salo, A, Tanaka, T., Hanj'u, S., Takiyama, Y., Nishizawa, M., 
Shimizu, N., Nomura, Y., Segawa, M., Iwabuchi, K, Eguchi, 1., Tanaka, H., Takahashi, H., Tsuji, S. 
Identification of the spinocerebellar ataxia type 2 gene using a direct identification of repeat expansion and 
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